<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Trifluoperazine versus placebo for schizophrenia - Koch, K - 2014 | Cochrane Library</title> <meta content="Trifluoperazine versus placebo for schizophrenia - Koch, K - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010226.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Trifluoperazine versus placebo for schizophrenia - Koch, K - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010226.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010226.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Trifluoperazine versus placebo for schizophrenia" name="citation_title"/> <meta content="Kai Koch" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="mzydkuk@nottingham.ac.uk" name="citation_author_email"/> <meta content="Kamel Mansi" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Euan Haynes" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Clive E Adams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Stephanie Sampson" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Vivek A Furtado" name="citation_author"/> <meta content="Institute of Mental Health" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010226.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010226.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010226.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010226.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Dyskinesia, Drug‐Induced [etiology]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Trifluoperazine [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010226.pub2&amp;doi=10.1002/14651858.CD010226.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010226\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010226\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010226.pub2",title:"Trifluoperazine versus placebo for schizophrenia",firstPublishedDate:"Jan 11, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010226.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010226.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010226.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010226.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010226.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010226.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010226.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010226.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010226.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010226.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1277 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010226.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-sec-0209"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-sec-0097"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-sec-0184"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/appendices#CD010226-sec-0219"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/table_n/CD010226StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/table_n/CD010226StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Trifluoperazine versus placebo for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#CD010226-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kai Koch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#CD010226-cr-0003">Kamel Mansi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#CD010226-cr-0004">Euan Haynes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#CD010226-cr-0005">Clive E Adams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#CD010226-cr-0006">Stephanie Sampson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information#CD010226-cr-0007">Vivek A Furtado</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information/en#CD010226-sec-0222">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010226.pub2">https://doi.org/10.1002/14651858.CD010226.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010226-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010226-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010226-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010226-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010226-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010226-abs-0001" lang="en"> <section id="CD010226-sec-0001"> <h3 class="title" id="CD010226-sec-0001">Background</h3> <p>Trifluoperazine is a long‐established high potency typical antipsychotic drug used in the treatment of schizophrenia and schizophrenia‐like illnesses. </p> </section> <section id="CD010226-sec-0002"> <h3 class="title" id="CD010226-sec-0002">Objectives</h3> <p>To determine absolute effects of trifluoperazine for schizophrenia and schizophrenia‐like illnesses compared with placebo. </p> <p>To critically appraise and summarise current evidence on the resource use, cost and economic evaluation of trifluoperazine compared with placebo for schizophrenia. </p> </section> <section id="CD010226-sec-0003"> <h3 class="title" id="CD010226-sec-0003">Search methods</h3> <p>Searches of the Cochrane Schizophrenia Group's register of trials (July 2012), supplemented with handsearching, reference searching, personal communication and contact with industry. Two review authors undertook a search for economic studies using the Cochrane Schizophrenia Group's Health Economic Database (CSzGHED) on the 9th April 2013. </p> </section> <section id="CD010226-sec-0004"> <h3 class="title" id="CD010226-sec-0004">Selection criteria</h3> <p>All available clinical randomised trials involving people with schizophrenia and schizophrenia‐like illnesses that compare trifluoperazine with placebo. </p> </section> <section id="CD010226-sec-0005"> <h3 class="title" id="CD010226-sec-0005">Data collection and analysis</h3> <p>Studies for the effects of interventions were reliably selected by a review team and data were doubly independently extracted to reduce bias. We only used dichotomous data, using intention‐to‐treat analysis when possible. Data were estimated using risk ratio (RR) with 95% confidence intervals (CI). A 'Summary of findings' table was produced, where possible, for each primary outcome using GRADE. Economic studies were searched and reliably selected by review authors (VF and SS) to provide an economic summary of available data. Where no relevant economic studies were eligible for inclusion, the economic review team valued the already‐included effectiveness outcome data to provide a rudimentary economic summary. </p> </section> <section id="CD010226-sec-0006"> <h3 class="title" id="CD010226-sec-0006">Main results</h3> <p>This review included 10 studies with a total number of 686 participants featuring in 20 different outcomes of interest. Overall, there was significant clinical improvement in clinical global state at medium term amongst people receiving trifluoperazine (3 RCTs, n = 417, RR 4.61, CI 1.54 to 13.84, <i>low quality evidence</i> ) and significantly fewer people receiving trifluoperazine left the studies early due to relapse or worsening at medium term (2 RCTs, n = 381, RR 0.34, CI 0.23 to 0.49, <i>low quality evidence</i> ). However, results were equivocal for leaving the study early at medium term for any reason (2 RCTs, n = 391, RR 0.80, CI 0.17 to 3.81, <i>very low quality evidence</i> ) and due to severe adverse effects (2 RCTs, n = 391, RR 1.54, CI 0.56 to 4.24, <i>very low quality evidence</i> ). Equivocal data were also found for intensified symptoms at medium term (2 RCTs, n = 80, RR 1.05, CI 0.54 to 2.05, <i>very low quality evidence</i> ) and rates of agitation or distress again at medium term (1 RCT, n = 52, RR 2.00, CI 0.19 to 20.72, <i>very low quality evidence</i>). Comparison between low and high‐dose trifluoperazine with placebo from a single study provided equivocal evidence of effects. For economic outcomes, we valued outcomes in GBP terms and presented them in additional tables; there was an estimated saving of £3488.3 in favour of trifluoperazine. However, numerous assumptions were made and these savings need to be interpreted in light of those assumptions. </p> </section> <section id="CD010226-sec-0007"> <h3 class="title" id="CD010226-sec-0007">Authors' conclusions</h3> <p>Our results agree with existing evidence that compared to placebo, trifluoperazine is an effective antipsychotic for people with schizophrenia. Furthermore, our review provides supportive evidence that trifluoperazine increases the risk of extrapyramidal adverse effects. Although the effect sizes against placebo are similar to those observed with other agents, they are based on data from many small, pre‐CONSORT trials with generally either a <i>low</i> or <i>very low GRADE evidence</i> that has limited implication for clinical practice. Large, independent trials are needed that adhere to the CONSORT statement to compare trifluoperazine with placebo used in the treatment of schizophrenia and schizophrenia‐like illnesses. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010226-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010226-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010226-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010226-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010226-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010226-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010226-abs-0004" lang="en"> <h3>Trifluoperazine versus placebo for schizophrenia</h3> <p>Trifluoperazine (trade name Stelazine) is a long‐established antipsychotic drug that has been used since the 1950s to treat schizophrenia. It is one of the first generation (typical) drugs that have proven very effective for treating the ‘positive symptoms’ of schizophrenia, such as hearing voices, seeing things and having strange beliefs. These drugs may cause side effects such as involuntary shaking, restlessness and movement disorders such as having a strange posture. </p> <p>There are also more modern drugs (second generation and atypical antipsychotic drugs). These are effective with the ‘positive symptoms’ of mental illness but also help treat ‘negative symptoms’ such as apathy, weight gain and loss of emotion in people with schizophrenia. These more modern drugs are much more expensive. </p> <p>This review is based on a search for trials carried out in July 2012, and includes 10 studies with 686 participants. The aim was to determine the effects of trifluoperazine for schizophrenia when compared with placebo (a ‘dummy’ treatment). As expected, people given trifluoperazine showed a significant improvement compared to placebo in both the short and medium term, reinforcing the use of this well‐established typical antipsychotic for people with schizophrenia. However, trifluoperazine can cause side effects such as confusion, agitation, having a dry mouth and blurred vision, but causes less sedation and dizzy spells, so is generally well tolerated by people with schizophrenia. </p> <p>The authors of the review conclude that trifluoperazine has similar effectiveness to other common antipsychotic drugs, although it may cause more side effects. Evidence used in the review was also graded as low or very low quality. In the light of this, use of other antipsychotic drugs should be considered before starting on trifluoperazine. Most of the included studies were conducted roughly 40 years ago so new, large, comprehensive and independent research trials are needed. </p> <p>This plain language summary has been written by a consumer Ben Gray from RETHINK.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010226-sec-0209" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010226-sec-0209"></div> <h3 class="title" id="CD010226-sec-0210">Implications for practice</h3> <section id="CD010226-sec-0210"> <section id="CD010226-sec-0211"> <h5 class="title">1. For people with schizophrenia</h5> <p>Trifluoperazine is a well‐recognised typical antipsychotic and this review has shown it does have a benefit over placebo, although adverse effects, particularly extrapyramidal side effects, are a major factor to consider. With the wide range of antipsychotics now available and the development of atypical antipsychotics, although personal preference, others may be more beneficial to try first which have shown to be more effective and have a reduced adverse‐effect profile. </p> </section> <section id="CD010226-sec-0212"> <h5 class="title">2. For clinicians</h5> <p>Clinicians and patients must collaborate to use the drug that is most suitable for the patient, with all relevant circumstances considered. In agreement with <a href="./references#CD010226-bbs2-0092" title="MarquesLO , LimaMS , SoaresBG . Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020] ">Marques 2004</a>, trifluoperazine has similar efficacy to other common antipsychotics although may contribute to more extrapyramidal events. In this light, use of potential other antipsychotics should be considered before starting on trifluoperazine. </p> </section> <section id="CD010226-sec-0213"> <h5 class="title">3. For managers/policy‐makers</h5> <p>Newer, larger and more comprehensive independent trials, to also include economic evaluation, are needed to compare trifluoperazine with other available antipsychotics rather than placebo, as it is well documented that trifluoperazine is an effective antipsychotic. If future evidence supports the existing evidence, that many typical antipsychotics are as effective as atypical antipsychotics, but also cost‐effective or cost‐beneficial, then a trend could be set to revert back to use of these less expensive drugs, particularly in the current economic climate. </p> </section> </section> <h3 class="title" id="CD010226-sec-0214">Implications for research</h3> <section id="CD010226-sec-0214"> <section id="CD010226-sec-0215"> <h5 class="title">1. General</h5> <p>Adherence to the CONSORT statement (<a href="./references#CD010226-bbs2-0072" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285(12):1987‐91. ">Moher 2001</a>) would probably have resulted in this review being more conclusive. Clear descriptions of randomisation would have reassured users of these trials that selection bias had been minimised and well described and tested blinding could have encouraged greater confidence in the control of performance and detection bias. As mentioned earlier in this review, studies did not report on design, methodology or analysis of their clinical trials. Therefore, it was not possible to assess the internal validity of the targeted studies. It was found that all studies used binary data, but none mentioned how they converted continuous data into binary and what methods they employed to do so. </p> </section> <section id="CD010226-sec-0216"> <h5 class="title">2. Specific</h5> <p>Most of the included studies were conducted roughly 40 years ago. Although not a priority question for funders to address, any future studies should adhere to the CONSORT statement in order to improve reporting standards (as described in <a href="#CD010226-sec-0199">Overall completeness and applicability of evidence</a>). Any further trials with the sole comparators of trifluoperazine versus placebo are unlikely, based on the available evidence and current accepted practice. The review authors have constructed a suggested design of future study with additional comparators should any new independent clinical trials using trifluoperazine ever be considered (See <a href="#CD010226-tbl-0006">Table 5</a>). </p> <div class="table" id="CD010226-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Suggested design for future research</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, clearly described, concealed.<br/> Blindness: double, described and tested.<br/> Duration: 12 months. </p> <p>Setting: community.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia or schizophrenia‐like illness, clearly described and documented.<br/> N = 600.*<br/> Age: any.<br/> Sex: both.<br/> Exclusion: none but full medical history must be taken into account as well as thorough health state evaluation to reduce potential confounders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Oral trifluoperazine: dose flexible within current guideline recommended limits <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, N = 150.<br/> 2. Oral clozapine: dose flexible within current guideline recommended limits <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, N = 150. </p> <p>3. Oral atypical antipsychotic: dose flexible current guideline within recommended limits <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, N = 150. </p> <p>**4. Oral placebo: N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All outcomes are grouped by time measured at: one month, three months, six months, nine months and 12 months.<br/> Mortality.<br/> Specific behaviours ‐ self‐harm, including suicide, injury to others, aggression.<br/> Global outcomes ‐ overall improvement, use of any relevant additional medication, relapse.<br/> Service outcomes ‐ hospital admission and duration of stay, for any reason.<br/> Mental state ‐ no clinically important change in general mental state, no clinically important change in psychotic symptoms, broken down into positive and negative symptoms.<br/> Adverse effects ‐ clinically important adverse effects, defining severe adverse effects and including all extrapyramidal phenomena.<br/> Leaving the study early ‐ any reason; severe adverse effects.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜20% between groups for primary outcome with adequate degree of certainty. </p> <p>** Issues about how ethical it is to give placebo to patients suffering with schizophrenia may arise, especially when all these drugs have been shown to be more beneficial than placebo in past RCTs. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RCT ‐ randomised controlled trial</p> </div> </div> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010226-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010226-sec-0022"></div> <div class="table" id="CD010226-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TRIFLUOPERAZINE versus PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TRIFLUOPERAZINE versus PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> TRIFLUOPERAZINE versus PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TRIFLUOPERAZINE versus PLACEBO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state ‐ clinical improvement ‐ medium term</b> <br/> As defined by each study<br/> Follow‐up: mean 19 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.61</b> <br/> (1.54 to 13.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>417<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> <br/> (31 to 282)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> <br/> (29 to 263)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state ‐ relapse or worsening ‐ medium term</b> <br/> Numbers of participants experiencing relapse/worsening<br/> Follow‐up: mean 5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.34</b> <br/> (0.23 to 0.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>381<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (90 to 191) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> <br/> (58 to 123) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state ‐ any clinically significant response in psychotic symptoms (as defined by each study) ‐ medium term</b> <br/> Numbers of participants experiencing 'intensified symptoms'<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.54 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>80<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b> <br/> (122 to 461) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b> <br/> (122 to 461) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early ‐ any reason ‐ medium term</b> <br/> Number of participants leaving the studies early<br/> Follow‐up: mean 5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.38 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>523<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,8,11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b><sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> <br/> (128 to 400) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b><sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (44 to 137) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Severe adverse effects ‐ short term</b> <br/> Numbers of participants leaving the studies due to severe adverse effects<br/> Follow‐up: mean 2 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.31</b> <br/> (0.22 to 7.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>67<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>8,9,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b> <br/> (17 to 600) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> <br/> (16 to 554) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Behaviour ‐ any clinically significant agitation or distress ‐ medium term</b> <br/> As defined by each study<br/> Follow‐up: 4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (7 to 797) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2</b> <br/> (0.19 to 20.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Moderate risk relates to the population percentage in the control group.<br/> <sup>2</sup> Median control group risk presented.<br/> <sup>3</sup> Data were presented as the positive outcome of 'clinical improvement' so the higher value indicates a favourable outcome.<br/> <sup>4</sup> Risk of bias: 'serious' ‐ 33% of the studies rated as a 'high' risk or bias over one or more of the domains; 100% of the included studies did not adequately describe randomisation methods.<br/> <sup>5</sup> Indirectness: 'serious' ‐ only 33% of the studies directly compared trifluoperazine to a placebo whereas 67% had other drug interventions in their respective trials.<br/> <sup>6</sup> Risk of bias: 'serious' ‐ 100% of the studies rated as a 'high' risk or bias over one or more of the domains; 100% of the included studies did not adequately describe randomisation methods.<br/> <sup>7</sup> Indirectness: 'serious' ‐ 50% of the studies directly compared trifluoperazine to a placebo whereas the remaining 50% had other drug interventions in their respective trials.<br/> <sup>8</sup> Imprecision: 'serious' ‐ 95% confidence intervals for best estimate of effect include both 'no effect' and appreciable benefit/harm.<br/> <sup>9</sup> Indirectness: 'serious' ‐ 100% had other drug interventions in their respective trials.<br/> <sup>10</sup> Note: moderate heterogeneity between studies.<br/> <sup>11</sup> Inconsistency: 'serious' ‐ moderate heterogeneity evident (I<sup>2</sup> = 47%).<br/> <sup>12</sup> Indirectness: 'serious' ‐ 20% of the studies directly compared trifluoperazine to a placebo whereas the remaining 80% had other drug interventions in their respective trials.<br/> <sup>13</sup> Risk of bias: 'serious' ‐ 50% of the studies rated as a 'high' risk or bias over one or more of the domains; 50% of the included studies did not adequately describe randomisation methods. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010226-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010226-sec-0023"></div> <section id="CD010226-sec-0024"> <h3 class="title" id="CD010226-sec-0024">Description of the condition</h3> <p>Schizophrenia is a term used for the most common form of psychiatric disorder characterised by psychotic symptoms, involving a change in a person’s thoughts, emotions, behaviour and perception of reality. It has an estimated mean incidence of 0.11 per 1000 population (range 0.07 to 0.17 per 1000) with a lifetime prevalence between 0.4% and 1.4% (<a href="./references#CD010226-bbs2-0074" title="NICE . Schizophrenia: Core interventions in the treatment and management in adults in primary and secondary care ‐ National Clinical Guideline Number 82. http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf. The British Psychological Society and The Royal College of Psychiatrists, 2010:4‐41. ">NICE 2010</a>). Onset is commonly during adolescence or young adulthood (<a href="./references#CD010226-bbs2-0081" title="SahaS , ChantD , WelhamJ , McGrathJ . Systematic review of the prevalence of schizophrenia. PLoS Medicine2005;2(5):0413‐33. [DOI: 10.137/journal.pmed.0020141] ">Saha 2005</a>) but can occur at any age, with mean age of onset about five years greater in women (<a href="./references#CD010226-bbs2-0074" title="NICE . Schizophrenia: Core interventions in the treatment and management in adults in primary and secondary care ‐ National Clinical Guideline Number 82. http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf. The British Psychological Society and The Royal College of Psychiatrists, 2010:4‐41. ">NICE 2010</a>). Symptoms are divided into positive and negative; positive symptoms encompass hallucinations, delusions and disordered thinking, whilst negative symptoms consist of social withdrawal and a loss of interest, energy and emotion (<a href="./references#CD010226-bbs2-0074" title="NICE . Schizophrenia: Core interventions in the treatment and management in adults in primary and secondary care ‐ National Clinical Guideline Number 82. http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf. The British Psychological Society and The Royal College of Psychiatrists, 2010:4‐41. ">NICE 2010</a>; <a href="./references#CD010226-bbs2-0079" title="Royal College of Psychiatrists. Schizophrenia. RCPSYCH2010. ">RCPSYCH 2010</a>). Although it is common to have a negative prodrome preceding positive symptoms, the course, duration and severity of schizophrenia varies considerably and is usually unique to each person (<a href="./references#CD010226-bbs2-0059" title="LankappaS , GandhiR . Quetiapine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD009935] ">Lankappa 2012</a>; <a href="./references#CD010226-bbs2-0074" title="NICE . Schizophrenia: Core interventions in the treatment and management in adults in primary and secondary care ‐ National Clinical Guideline Number 82. http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf. The British Psychological Society and The Royal College of Psychiatrists, 2010:4‐41. ">NICE 2010</a>). People with schizophrenia have higher risk mortality than the general population due to increased rates of death through suicide and accidents as well as organic diseases such as cardiovascular, renal and respiratory disease (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>; <a href="./references#CD010226-bbs2-0082" title="SahaS , ChantD , McGrathJ . A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?. Archives of General Psychiarty2007;64(10):1123‐31. [DOI: 10.1001/archpsyc.64.10.1123] ">Saha 2007</a>; <a href="./references#CD010226-bbs2-0086" title="TiihonenJ , LonnqvistJ , WahlbeckK , KlaukkaT , NiskanenL , TanskanenA , et al. 11‐year follow‐up of mortality in patients with schizophrenia: a population‐based cohort study (FIN11 study). Lancet2009;374(9690):620‐7. ">Tiihonen 2009</a>). Furthermore, people with schizophrenia experience social problems including social exclusion, reduced employment opportunities , problems with relationships and a lack of public understanding of the disorder creating a harmful stigma (<a href="./references#CD010226-bbs2-0074" title="NICE . Schizophrenia: Core interventions in the treatment and management in adults in primary and secondary care ‐ National Clinical Guideline Number 82. http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf. The British Psychological Society and The Royal College of Psychiatrists, 2010:4‐41. ">NICE 2010</a>). Key treatment for this illness is medication. This has been shown to be of benefit for at least 'positive symptoms', but effectiveness relies largely on adherence. Unfortunately, these medications are not without their adverse effects, which highlights the importance of selecting the right medication and thoughtfully involving the recipient of care in the process. </p> </section> <section id="CD010226-sec-0025"> <h3 class="title" id="CD010226-sec-0025">Description of the intervention</h3> <p>Trifluoperazine, trade name Stelazine, is a long‐established antipsychotic that has been used since the 1950s to treat schizophrenia. It is one of the first generation (typical) drugs that has a high potency, having a greater bind to the D2 receptor (<a href="./references#CD010226-bbs2-0087" title="TurnerT . Chlorpromazine: unlocking psychosis. BMJ2007;334(Suppl 1):s7. ">Turner 2007</a>). As with most first generation drugs, trifluoperazine is known to cause extrapyramidal side effects (EPS), including pseudo‐Parkinsonism, dystonia, akathisia and tardive dyskinesia. There is no clear choice of first‐line antipsychotics for schizophrenia as the efficacy of the drugs available is not too dissimilar and the choice of medication is usually made based on availability, cost, side‐effect profile and individual patient circumstances (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>). Newer generation (atypical) drugs have become available and claim to be more effective in treating negative symptoms with fewer EPS, however systematic reviews have demonstrated that this claim by the pharmaceutical industry is not always accurate (<a href="./references#CD010226-bbs2-0060" title="LeuchtS , WahlbeckK , HamannJ , KisslingW . New generation antipsychotics versus low‐potency conventional antipsychotics: a systematic review and meta‐analysis. Lancet2003;361(May 10):1581‐9. ">Leucht 2003</a>). </p> </section> <section id="CD010226-sec-0026"> <h3 class="title" id="CD010226-sec-0026">How the intervention might work</h3> <p>Pharmacodynamics of trifluoperazine: it is a high potency derivative of phenothiazine and is chemically related to chlorpromazine. It causes a post‐synaptic D2 dopamine receptor blockade in the brain, specifically the mesolimbic, mesocortical centres and the striatum, the latter of which is responsible for EPS (<a href="./references#CD010226-bbs2-0027" title="AranaG , RosenbaumJ . Handbook of Psychiatric Drug Therapy. USA. 4. Philadelphia: Lippincott Williams and Wilkins, 2000. ">Arana 2000</a>). Because of a decrease in homovanillic acid levels (primary dopamine metabolite), clinical effects of trifluoperazine normally take weeks to occur (<a href="./references#CD010226-bbs2-0029" title="Bazire . Psychotropic Drug Directory. USA. New York: Butler and Tanner Limited, 2000. ">Bazire 2000</a>). It has weak anticholinergic and sedative effects whilst having strong extrapyramidal and antiemetic effects. Trifluoperazine is readily absorbed by the gastrointestinal tract (GI) and will peak in the plasma after one and a half to six hours. It is a protein‐binding drug and so will influence secretion into breast milk (care must be taken for pregnant or breast feeding women). Trifluoperazine has a low potency of cholinergic blockade and causes parasympatholytic side effects such as confusion, agitation, dry mouth and blurred vision. It weakly acts at histamine and alpha‐adrenergic receptors relative to the other typical antipsychotics causing less sedation and orthostatic hypotension, hence is generally well tolerated (<a href="./references#CD010226-bbs2-0056" title="KaplanH , SadockB . Pocket Handbook of Clinical Psychiatry. USA. 2. New York: Williams and Wilkins, 1998. ">Kaplan 1998</a>). </p> </section> <section id="CD010226-sec-0027"> <h3 class="title" id="CD010226-sec-0027">Why it is important to do this review</h3> <p>Trifluoperazine is a well‐established antipsychotic drug used to treat schizophrenia. The previous trifluoperazine Cochrane review was undertaken nearly a decade ago (<a href="./references#CD010226-bbs2-0092" title="MarquesLO , LimaMS , SoaresBG . Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020] ">Marques 2004</a>) and does include a placebo comparison. Although relative effects of trifluoperazine against other antipsychotic drugs are important, establishing an up‐to‐date absolute measure of clinical outcomes, efficacy and effects of this less expensive drug is needed. More recently, there has been a shortage of supplies of oral trifluoperazine tablets in the UK and there is emerging evidence that patients receiving this medication who were under the care of their GPs for schizophrenia are beginning to relapse and seek input from secondary care (see: <a href="./references#CD010226-bbs2-0071" title="Mental Health Care: reliable and up‐to‐date information about psychosis for family members and friends. http://www.mentalhealthcare.org.uk/pharmacist_answers_september_august_2011accessed September 2013. ">Mental Health Care</a> and <a href="./references#CD010226-bbs2-0076" title="PJ Online: Do you accept that medicine shortages have not harmed patients?. http://www.pjonline.com/poll/do_you_accept_that_medicine_shortages_have_not_harmed_patientsAccessed September 2013. ">PJ Online</a>). </p> <p>In terms of the costs of schizophrenia, this was estimated at about £6.7 billion in England in 2004/2005, of which the direct costs were £2 million, while the indirect costs accounted for the rest (<a href="./references#CD010226-bbs2-0067" title="MangaloreR , KnappM . Cost of schizophrenia in England. Journal of Mental Health Policy and Economics2007;10(1):23‐41. ">Mangalore 2007</a>). The cost of trifluoperazine itself is inexpensive, at £5.87 for 112 5 mg tablets. Every person who needs trifluoperazine, in general, requires about 15 mg a day (or 450 mg per month) costing £4.72 (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>). The newer, atypical antipsychotics in comparison are more expensive than typical antipsychotics, with olanzapine available at £13.11 for 28 5 mg tablets, and clozapine (Clozaril) at £21.56 for 28 100 mg tablets. </p> <p>It is essential to complement the clinical effectiveness of trifluoperazine with its cost‐effectiveness. Davies et al. (<a href="./references#CD010226-bbs2-0034" title="DaviesLM , LewisS , JonesPB , BarnesTR , GaughranF , HayhurstK , et al. Cost‐effectiveness of first‐ v. second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry2007;191:14‐22. ">Davies 2007</a>) conducted a study on cost‐effectiveness of the first generation antipsychotics (i.e. flupenthixol, trifluoperazine, chlorpromazine) and the second generation antipsychotics (i.e. risperidone, olanzapine, amisulpiride). The study findings argue that there is no evidence to suggest that atypical (second generation) antipsychotics are more cost‐effective than typical (first generation) antipsychotics. Recommended first‐line treatment for schizophrenia are second‐generation antipsychotic medications, which tend to be more expensive than first‐generation antipsychotics; it is therefore important to assess the effectiveness and cost‐effectiveness of the older medications. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010226-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010226-sec-0028"></div> <p>To determine absolute effects of trifluoperazine for schizophrenia and schizophrenia‐like illnesses when compared with placebo. </p> <p>To critically appraise and summarise current evidence on the resource use, cost and economic evaluations of trifluoperazine for schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010226-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010226-sec-0029"></div> <section id="CD010226-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010226-sec-0031"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials. If a trial was described as 'double blind' but implied randomisation, we included such trials in a sensitivity analysis (see <a href="#CD010226-sec-0089">Sensitivity analysis</a>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in important clinically significant, but not necessarily statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory. We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments within trifluoperazine, we only included data if the adjunct treatment was evenly distributed between groups and it was only the trifluoperazine that was randomised. </p> <p>With regards to selecting studies for economic evaluations, review authors (SS and VF) categorised studies as per the following:<br/> <br/> <b>Type A</b> ‐ Full economic evaluation (within the framework of RCT): studies that focus on cost‐effectiveness analysis, cost‐utility analysis and cost‐benefit analysis.<br/> <b>Type B</b> ‐ Partial economic evaluation (within the framework of RCT): studies that focus on cost‐analysis and cost‐minimisation studies of trifluoperazine.<br/> <b>Type C</b> ‐ Randomised trials that reported limited information, such as estimates of resources use or costs associated with trifluoperazine. </p> </section> <section id="CD010226-sec-0032"> <h4 class="title">Types of participants</h4> <p>Participants with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis. </p> <p>We were interested in making sure that information was as relevant to the current care of people with schizophrenia as possible. We therefore sought to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD010226-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD010226-sec-0034"> <h5 class="title">1. Trifluoperazine</h5> <p>Any dose administered by any means. We sought to keep to <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a> doses ‐ "initially 5 mg twice daily, increased by 5 mg daily after 1 week, then at intervals of 3 days, according to the response; elderly reduce initial dose by at least half" ‐ and to consider any dose over 30 mg as very high. Doses outside this range were further investigated using sensitivity analysis. </p> </section> <section id="CD010226-sec-0035"> <h5 class="title">2. Placebo</h5> <p>Any form of placebo or no treatment alternative.</p> </section> </section> <section id="CD010226-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We divided all outcomes into short term (less than three months), medium term (three to six months) and long term (over six months). </p> <section id="CD010226-sec-0037"> <h5 class="title">Primary outcomes</h5> <p><b>1. Global state</b> <br/> 1.1 Any clinically significant response in medium term global state (as defined by each study). </p> <p><b>2. Behaviour</b> <br/> 2.1 Any clinically significant agitation or distress (as defined by each study). </p> <p><b>3. Relapse +/‐ hospitalisation</b> <br/> 3.1 Relapse including any hospitalisation of a participant within a study. </p> <p><b>4. Severe adverse effects</b> <br/> 4.1 Any clinically significant severe short term adverse effects based on relevant rating scales. </p> </section> <section id="CD010226-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p><b>1. Global state</b> <br/> 1.1 Average score/change in global state ‐ short and long term.<br/> 1.2 Relapse. </p> <p><b>2. Behaviour</b> <br/> 2.1 Use of adjunctive medication for sedation.<br/> 2.2 Aggression to self or others. </p> <p><b>3. Mental state</b> <br/> 3.1 Any clinically significant response in psychotic symptoms.<br/> 3.2 Average score/change in psychotic symptoms.<br/> 3.3 Any clinically significant response in positive symptoms.<br/> 3.4 Average score/change in positive symptoms.<br/> 3.5 Any clinically significant response in negative symptoms.<br/> 3.6 Average score/change in negative symptoms. </p> <p><b>4. Leaving the study early</b> <br/> 4.1 Any reason.<br/> 4.2 Due to adverse effects.<br/> 4.3 Due to relapse. </p> <p><b>5. Extrapyramidal adverse effects</b> <br/> 5.1 Use of any anti‐Parkinsonism drugs.<br/> 5.2 Average score/change in extrapyramidal adverse effects.<br/> 5.3 Tardive dyskinesia.<br/> 5.4 Acute dystonia.<br/> 5.5 Akathisia.<br/> 5.6 Pseudo‐Parkinsonism. </p> <p><b>6. Other adverse effects/event, general and specific</b> <br/> 6.1 Death. </p> <p><b>7. Hospital and service utilisation outcomes</b> <br/> 7.1 Hospital admission.<br/> 7.2 Average change in days in hospital.<br/> 7.3 Improvement in hospital status (for example: change from formal to informal admission status, use of seclusion, level of observation). </p> <p><b>8. Economic outcomes</b> </p> <p>8.1 Average change in total cost of medical and mental health care.<br/> 8.2 Total indirect and direct costs.<br/> 8.3 Direct resource use:<br/> <i>8.3.1 Outpatients ‐ number of contacts (GP consultation, psychiatrist, psychologists, psychiatric nurse, counsellor, social worker).</i> <br/> <i>8.3.2 Hospitalisation (taking battery of tests, patients’ physical, psychiatric and psychological profile and psychological assessment, number of days, relapse).</i> <br/> <i>8.3.3 Medication (different types of antipsychotics to include dose and frequency, treatment of side‐effects).</i> <br/> <i>8.3.4 Psychological therapies (different types of psychological therapies to include session numbers and frequency)</i> <br/> <i>8.3.5Other resources (day centres, night shelter) and transportation for medical care visits.</i> <br/> 8.4 Indirect resource use:<br/> <i>8.4.1 Family, relative and friends resources.</i> <br/> <i>8.4.2 Police, criminal justice system.</i> <br/> <i>8.4.3 Benefits paid, social security payments.</i> <br/> <i>8.4.4 Employment agency workers, absence from work, loss of productivity.</i> <br/> 8.5 Cost‐effectiveness ratios represented by ICER.<br/> 8.6 Cost‐utilities represented by incremental costs per QALY or DALYs <br/> 8.7 Cost benefit represented by net Benefit Ratio, others. </p> <p><b>9. Quality of life/satisfaction with care for either recipients of care or caregivers</b> <br/> 9.1 Significant change in quality of life/satisfaction.<br/> 9.2 Average score/change in quality of life/satisfaction. </p> <p><b>10. Cognitive response</b> <br/> 10.1 Any clinically important change.<br/> 10.2 Any change, general and specific. </p> <section id="CD010226-sec-0039"> <h6 class="title">11. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD010226-bbs2-0083" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used GRADE profiler (<a href="http://ims.cochrane.org/gradepro" target="_blank">GRADEPRO</a>) to import data from RevMan 5.1 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p>1. Global state ‐ any clinically significant response in global state ‐ medium term.<br/> 2. Global state ‐ relapse +/‐ hospitalisation ‐ medium term.<br/> 3. Mental state ‐ any clinically significant response in psychotic symptoms ‐ medium term.<br/> 4. Leaving the study early ‐ medium term.<br/> 5. Severe adverse side effects ‐ short term.<br/> 6. Behaviour ‐ any clinically significant response in behaviour ‐ medium term.<br/> 7. Economic outcomes. </p> </section> </section> </section> </section> <section id="CD010226-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010226-sec-0041"> <h4 class="title">Electronic searches</h4> <section id="CD010226-sec-0042"> <h5 class="title">1. Cochrane Schizophrenia Group Trial Register</h5> <p>We searched the Cochrane Schizophrenia Group's register (May 2012), which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. Trifluoperazine is known by many names, so we constructed the following search phrase to assist identification using the following search strategy: </p> <p>Trifluoperazine‐phrase = *10‐[3‐(4‐methyl‐1‐piperazinyl)propyl]‐2‐trifluoromethylpheno thiazine (hydrochloride)* or *terfluzine* or *terfluzinor discimer* or *eskazine foille* or *iremo* or *piero* or *jatroneural* or *modalina* or *oxyperazine* or *sedofren* or *sporalon* or *stelazine* or *stelazina* or *stelium* or *terflurazine* or *terfluoperazine* or *SKF 5019* or *7623 RP* or *trifluoperazine* or *Solazine*. </p> <p>See <a href="#CD010226-sec-0219">Appendices</a> for details of the original search. </p> </section> <section id="CD010226-sec-0043"> <h5 class="title">2. Cochrane Schizophrenia Group Health Economic Database</h5> <p>For the economic search, the economic review team replicated the above strategy in the Cochrane Schizophrenia Group Health Economic Database (CSzGHED), 9th April 2013. The database of studies relates to cost‐effectiveness of schizophrenia treatments. This database was constructed from systematic searches of four databases: Health Economic Evaluation Database (<a href="./references#CD010226-bbs2-0052" title="Health Economic Evaluation Database (HEED). Online ISBN: 9780470510933. [DOI: 10.1002/9780470510933] ">HEED</a>), National Health Services Health Economic Database (<a href="http://www.crd.york.ac.uk/crdweb/homepage.asp" target="_blank">NHS EED</a>), Cost‐Effectiveness Analysis Registry (<a href="./references#CD010226-bbs2-0033" title="Cost‐Effectiveness Analysis Registry (CEA). https://research.tufts‐nemc.org/cear4/ accessed 11/09/13. ">CEA</a>) and <a href="http://www.aeaweb.org/econlit/" target="_blank">EconLit</a> as well as <a href="http://www.thecochranelibrary.com/view/0/index.html" target="_blank">Cochrane Registry</a>. </p> </section> </section> <section id="CD010226-sec-0044"> <h4 class="title">Searching other resources</h4> <section id="CD010226-sec-0045"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD010226-sec-0046"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD010226-sec-0047"> <h3 class="title" id="CD010226-sec-0047">Data collection and analysis</h3> <section id="CD010226-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Review author KM independently inspected citations from the searches and identify relevant abstracts. A random 20% sample was independently re‐inspected by review authors KK and EH to ensure reliability. Where disputes arose, the full report was acquired for more detailed scrutiny. Full reports of the abstracts meeting the review criteria were obtained and inspected by KM. Again, a random 20% of reports were re‐inspected by KK and EH in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we contacted the authors of the study for clarification. </p> <p>For the selection of economic studies, two authors (VF and SS) inspected all retrieved citations identified by the economic database search, and where disputes arose, the full report was acquired for further inspection. </p> </section> <section id="CD010226-sec-0049"> <h4 class="title">Data extraction and management</h4> <section id="CD010226-sec-0050"> <h5 class="title">1. Extraction</h5> <p>Review author KM extracted data from all included studies. In addition, to ensure reliability, KK and EH independently extracted data from a random sample of these studies, comprising 10% of the total. Again, any disagreements were discussed, decisions documented and, if necessary, authors of studies contacted for clarification. With remaining problems KM, KK and EH helped to clarify issues and these final decisions were documented. Data presented only in graphs and figures were extracted whenever possible, but included only if two review authors independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. Had we identified multi‐centre studies, we would have extracted data relevant to each component centre separately; however, we found no multi‐centre studies to include. </p> <p>For the economic analysis, studies of Type A and B (see <a href="#CD010226-sec-0031">Types of studies</a>), were investigated by VF and SS, investigated whether appraisal had already been undertaken by the National Health Service's Economic Evaluation Database (<a href="http://www.crd.york.ac.uk/crdweb/homepage.asp" target="_blank">NHS EED</a>) using their search tool derived for this purpose. If appraisal had not been undertaken, we applied this tool to the data. In this current review, there were only Type C studies available; therefore, we extracted outcome data directly from the already‐included effectiveness studies. We recognised that much information would be lacking to get results that are both valid and reliable (this is a pilot economic study and there is a risk that the results may be incorrect). </p> </section> <section id="CD010226-sec-0051"> <h5 class="title">2. Management</h5> <section id="CD010226-sec-0052"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD010226-sec-0053"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We would have included continuous data from rating scales only if:<br/> <br/> a) the psychometric properties of the measuring instrument were described in a peer‐reviewed journal (<a href="./references#CD010226-bbs2-0068" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument was not written or modified by one of the trialists for that particular trial.<br/> <br/> Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, in <a href="#CD010226-sec-0098">Description of studies</a> we would have noted if this was the case or not. However, no scale‐derived data were found to include in this review. </p> </section> <section id="CD010226-sec-0054"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult to measure conditions such as schizophrenia. Had we found any scale data to include, we had decided that we would primarily use endpoint data, and only use change data if the former were not available. Endpoint and change data would have been combined in the analysis, with mean differences (MD) rather than standardised mean differences (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Again, we found no such data to be included. </p> </section> <section id="CD010226-sec-0055"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we would have applied the following standards to all data before inclusion:<br/> <br/> a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors;<br/> b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<a href="./references#CD010226-bbs2-0026" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>);<br/> c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), (<a href="./references#CD010226-bbs2-0057" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>)), which can have values from 30 to 210), the calculation described above is modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and 'S min' is the minimum score. </p> <p>Endpoint scores on scales often have a finite start and end point and these rules can be applied. Skewed data pose less of a problem when looking at means if the sample size is large (&gt; 200) and we would have entered these into the syntheses. We would have presented skewed endpoint data from studies of less than 200 participants in ‘Additional tables’ rather than enter such data in analyses.<br/> <br/> When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We would have presented and entered change data into analyses. However, we found no such data. </p> </section> <section id="CD010226-sec-0056"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we would have converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). However, we found no such variables. </p> </section> <section id="CD010226-sec-0057"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Had we found any continuous data, we would have made the effort to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD010226-bbs2-0075" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD010226-bbs2-0057" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD010226-bbs2-0061" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005</a>; <a href="./references#CD010226-bbs2-0062" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>). </p> </section> <section id="CD010226-sec-0058"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for trifluoperazine. Where keeping to this makes it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not improved') we reported data where the left of the line indicates an unfavourable outcome. This is noted in the relevant graphs, and is the case for the outcome of 'clinical improvement'. </p> </section> </section> </section> <section id="CD010226-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Again, review authors KM, KK and EH worked independently to assess risk of bias by using criteria described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters disagreed, the final rating was made by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted the authors of the studies in order to obtain further information. Non‐concurrence in quality assessment was reported, but when disputes arose as to which category a trial is to be allocated, again, we resolved this by discussion. </p> <p>The level of risk of bias is noted in both the text of the review and in the <a href="./full#CD010226-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>This review also aimed to assess the overall methodological quality of each study included in the economic evaluation. Assessment of risk bias was carried out using the checklist developed by <a href="./references#CD010226-bbs2-0038" title="DrummondMF , JeffersonTO . Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ1996;313(3 August):275‐83. ">Drummond 1996</a> and the CHEC criteria list (<a href="./references#CD010226-bbs2-0041" title="EversS , GoossensM , deVetH , vanTulderM , AmentA . Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care2005;21(2 Spring):240‐5. ">Evers 2005</a>) for Type A and B studies. Had we found any economic studies of Type A or B level, this would have been noted in the summary as well as in <a href="#CD010226-tbl-0002">Table 1</a>. In this current review, only Type C level studies were used, and therefore the same judgement for risk of bias was employed as for the effectiveness studies. </p> <div class="table" id="CD010226-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Economic summary</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Perspective</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of Economic Evaluation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resource Use provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unit Costs Provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICER</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QALY/DALY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Net Benefit Ratio</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grading</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </section> <section id="CD010226-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010226-sec-0061"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD010226-bbs2-0032" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD010226-bbs2-0035" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). For statistically significant results, we used 'Summary of findings' tables to calculate the number needed to treat to provide benefit /to induce harm (NNTB/H) statistic and its 95% CI. </p> </section> <section id="CD010226-sec-0062"> <h5 class="title">2. Continuous data</h5> <p>Had we encountered continuous data, we would have estimated mean difference (MD) between groups. We would prefer not to calculate effect size measures (standardised mean difference(SMD)). However, if scales of very considerable similarity had been used, we would have presumed there was a small difference in measurement, and would have calculated the effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD010226-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <section id="CD010226-sec-0064"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD010226-bbs2-0036" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD010226-bbs2-0030" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD010226-bbs2-0048" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>We did not find any cluster‐randomised trials. If clustering had not been accounted for in primary studies, we planned to present the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD010226-bbs2-0048" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD010226-bbs2-0037" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC is not reported, it will be assumed to be 0.1 (<a href="./references#CD010226-bbs2-0088" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> </section> <section id="CD010226-sec-0065"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD010226-bbs2-0040" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we would have only used data of the first phase of cross‐over studies. However, no such studies were found. </p> </section> <section id="CD010226-sec-0066"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>There were no studies incorporating multiple treatment groups; however, for future versions of this review, where a study involves more than two treatment arms, if relevant, the additional treatment arms would be presented in comparisons. If data are binary these would be simply added and combined within the two‐by‐two table. If data are continuous we would combine the data following the formula in section 7.7.3.8  (Combining groups) of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Where the additional treatment arms are not relevant, we will not use these data. </p> </section> </section> <section id="CD010226-sec-0067"> <h4 class="title">Dealing with missing data</h4> <section id="CD010226-sec-0068"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD010226-bbs2-0091" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, where more than 50% of data were unaccounted for, we did not reproduce these data or use them within analyses, (except for the outcome 'leaving the study early'). When, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias. This was the case in <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>. </p> </section> <section id="CD010226-sec-0069"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes the rate of those who stayed in the study ‐ in that particular arm of the trial ‐ were used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who complete the study to that point are compared to the ITT analysis using the above assumptions. </p> </section> <section id="CD010226-sec-0070"> <h5 class="title">3. Continuous</h5> <section id="CD010226-sec-0071"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we would have reproduced these. However, no continuous data were found. </p> </section> <section id="CD010226-sec-0072"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we would first have tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either a 'P' value or 't' value available for differences in mean, we would calculate them according to the rules described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics. If these formulae do not apply, we would calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD010226-bbs2-0044" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless would examine the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD010226-sec-0073"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD010226-bbs2-0063" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, if LOCF data were used in the trial, if less than 50% of the data have been assumed, we would have presented and used these data and indicated that they were the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD010226-sec-0074"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD010226-sec-0075"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, these were fully discussed. </p> </section> <section id="CD010226-sec-0076"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, these were fully discussed. </p> </section> <section id="CD010226-sec-0077"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD010226-sec-0078"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD010226-sec-0079"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD010226-bbs2-0054" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<sup>2</sup>  test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD010226-sec-0085">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD010226-sec-0080"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD010226-sec-0081"> <h5 class="title">1. Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We sought to locate protocols of included randomised trials. If the protocol had been available, outcomes in the protocol and in the published report would have been compared. However, no protocols were available, so outcomes listed in the methods section of the trial report were compared with actually reported results. </p> </section> <section id="CD010226-sec-0082"> <h5 class="title">2. Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD010226-bbs2-0039" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are again described in Section 10 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We intended not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In this version of the review, no funnel plots were used, because no single outcome included 10 or more studies. </p> </section> </section> <section id="CD010226-sec-0083"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose a random‐effects model for all analyses. </p> <section id="CD010226-sec-0084"> <h5 class="title">Pilot Economic Summary</h5> <p><i>“It has been argued for many years that promoting effective care without taking into account the cost of care and the value of any health gain can lead to inefficient use of public and private funds allocated to health care, which may indirectly result in harm for individuals and the public”</i> (<a href="./references#CD010226-bbs2-0089" title="Williams , A(editor) . Health economics: the cheerful face of dismal science?. Health and economics. London (UK): Macmillan, 1987. ">Williams 1987</a>). </p> <p>We intended to summarise data from type A and type B studies. Data were summarised according to the Cochrane Campbell Economic Methods Group (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and if information had been available, a narrative abstract would have been presented for each included study in (see <a href="#CD010226-tbl-0002">Table 1</a>). </p> <p>We anticipated that most studies would be Type C level of economic evidence and that we would use data from such studies to calculate a GBP value associated with the outcomes. These approximate values were calculated by (a) using the Personal Social Services Research Unit (PSSRU ‐ NHS reference costs for mental health services) calculation of £338 (weighted mean average of all adult mental health inpatient bed days) per hospital bed day based in a UK NHS setting (<a href="./references#CD010226-bbs2-0077" title="Compiled by LesleyCurtis . Unit costs of health and social care 2012. http://www.pssru.ac.uk/project‐pages/unit‐costs/2012/ (accessed May 2013)2012:47. ">PSSRU 2012</a>), and (b) <i>assuming</i> that one relapse equals one hospital admission, a median length of stay as 16 days, as per Hospital Episode Statistics 2012 (<a href="./references#CD010226-bbs2-0053" title="Hospital Episode Statistics, Admitted Patient Care ‐ England 2011‐12: Main Specialties (.xls). http://www.hscic.gov.uk/searchcatalogue?productid=9161&amp;q=title%3a%22hospital+episode+statistics%22&amp;sort=Relevance&amp;size=10&amp;page=1#top (accessed May 2013) 2011‐12. ">HES 2012</a>; main speciality ‘adult mental illness’), we utilised results of the effects of the intervention that presented service use data for an adult ward as well as for relapse rates (HES is a data warehouse containing details of all admissions, outpatient appointments and A&amp;E attendances at NHS hospitals in England) (c) assuming that the adjunctive medication used was phenobarbital and that it would be prescribed for no longer than 14 days at an average dose of 120 mgs per day. The cost for this was obtained from the BNF which provides unit costs for the medication (d) assuming that for the treatment of extra‐pyramidal side‐effects, procyclidine was used at a dose of 10 mgs three times a day for 14 days. The cost for this was obtained from the BNF which provides unit costs for the medication (e) assuming that for the treatment of akathesia, propranolol was prescribed at a dose of 80 mgs twice a day for 14 days. The cost for this was obtained from the BNF which provides unit costs for the medication. </p> <p>We have not factored any associated costs (including cost and resource use of treatment) prior to the relevant measured outcomes being considered. We are using UK NHS PSSRU reference costs of 2012 as well as BNF costs from 2013 and therefore present the outcomes in terms of a GBP saving using relative risks obtained from the effectiveness part of the review, which we have considered to be a proxy for resource use. </p> <p>The authors wish to emphasise the numerous assumptions that have been made for the purposes of presenting this economic data, specifically at Type C studies: </p> <p> <ol id="CD010226-list-0001"> <li> <p>The current included studies contributing to the Type C studies were undertaken between the years of 1961 to 1975; and, taking this into account ‐ </p> </li> <li> <p>The average length of stay and costs have been calculated from current available data, that is, according to 2012 HES costs, from most primarily a UK NHS perspective; and </p> </li> <li> <p>The GBP value data that are presented reflect a proxy measure only; that is, the GBP value of the intervention effect on the measured outcome, and not taking into account any costs or resource use that may likely have been incurred prior to the actual outcome (which includes, but is not limited to, costs and resource use prior to intervention, the intervention itself and post‐intervention up to outcome).. </p> </li> </ol> </p> <p>We are aware that Cochrane systematic reviews are international in context and in reception; however, we have adopted a UK NHS perspective for the purposes of this review – partly because we have been funded by the National Institute of Health Research (NIHR) (NIHR Cochrane Programme Grant 2011, UK Reference number: 10/4001/15) to undertake a series of economic evaluations within systematic reviews. </p> <p><i>“…[I]n the face of scarce resources, decision makers often need to consider not only whether an intervention works, but also whether its adoption will lead to a more efficient use of resources”</i> (<a href="./references#CD010226-bbs2-0055" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>The comparisons considered in this review involve trifluoperazine (treatment) versus placebo. The value of incorporating consideration of the economics of a treatment versus placebo comparison is extremely limited, since in practice patients are not treated with placebo. We are aware that any economic analysis of a treatment versus placebo comparison, any apparent differences between comparison groups in terms of resource use or costs are likely to be overestimated (relative to a treatment versus alternative treatment comparison) and are therefore unlikely to be applicable to any target setting (assuming that an alternative treatment is more effective than placebo), thus limiting the value of such an analysis for end users. However, we believe, at least for schizophrenia, placebo (or nothing) is often the clinical option chosen by the person with the illness, and to consider the economic issues surrounding this seems sensible (<a href="./references#CD010226-bbs2-0028" title="BartkoG , HerczegI , ZadorG . Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatrica Scandinavica1988;77(1):74‐6. ">Bartko 1988</a>). </p> </section> </section> <section id="CD010226-sec-0085"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD010226-sec-0086"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD010226-sec-0087"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of trifluoperazine for people with schizophrenia in general. In addition, however, we wanted to report data on subgroups of people in the same clinical state, stage and with similar problems. All participants in the included studies were classified as chronic schizophrenia; however, perhaps owing to the age of the included studies and low‐quality reporting standards, details of individual participants were not provided, meaning that subgroup analyses were not possible. We have, however, presented details for trifluoperazine high dose versus placebo and low dose versus placebo separately. </p> </section> </section> <section id="CD010226-sec-0088"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, this was reported. First, we investigated whether data were entered correctly. Second, if data were correct, we visually inspected the graph and outlying studies were successively removed to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, data would be presented. If not, data were not pooled and issues were discussed. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these. </p> </section> </section> <section id="CD010226-sec-0089"> <h4 class="title">Sensitivity analysis</h4> <section id="CD010226-sec-0090"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies. </p> </section> <section id="CD010226-sec-0091"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD010226-sec-0067">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption. </p> <p>Had we found continuous data, and made assumptions regarding missing SDs data (see <a href="#CD010226-sec-0067">Dealing with missing data</a>), we would have compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis would have been undertaken to test how prone results were to change when completer‐only data only were compared to the imputed data using the above assumption. If there was a substantial difference, we would have reported results and discussed them but would have continued to employ our assumption. However, no such data were found. </p> </section> <section id="CD010226-sec-0092"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then data from these trials were included in the analysis. </p> </section> <section id="CD010226-sec-0093"> <h5 class="title">4. Imputed values</h5> <p>We would have also undertaken a sensitivity analysis to assess the effects of including data from trials where we would have used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If substantial differences were noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but would have presented them separately. Again, no such data were imputed. </p> </section> <section id="CD010226-sec-0094"> <h5 class="title">5. Fixed and random effects</h5> <p>All data were synthesised using a random‐effects model, however, we also synthesised data for the primary outcome using a fixed‐effect model to evaluate whether this altered the significance of the results. </p> </section> <section id="CD010226-sec-0095"> <h5 class="title">6. Unusual doses of trifluoperazine</h5> <p>Again, only working with primary outcomes, we investigated whether doses over 30 mg of trifluoperazine had any different effects than more modest doses. </p> </section> <section id="CD010226-sec-0096"> <h5 class="title">7. Economic summary</h5> <p>We undertook a sensitivity analysis taking into account both the upper and lower confidence intervals for the risk ratios, of the outcomes of interest, and calculated a saving based on these values to investigate how far this affects the direction of the estimated value. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010226-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010226-sec-0097"></div> <section id="CD010226-sec-0098"> <h3 class="title">Description of studies</h3> <p>For in‐depth descriptions of the studies please see <a href="./references#CD010226-sec-0228" title="">Characteristics of included studies</a><a href="./references#CD010226-sec-0229" title="">Characteristics of excluded studies</a>, and <a href="./references#CD010226-sec-0230" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD010226-sec-0099"> <h4 class="title">Results of the search</h4> <section id="CD010226-sec-0100"> <h5 class="title">1. Effects of intervention</h5> <p>The electronic search (9 July 2012) identified more than 500 empirical clinical studies which were potentially eligible for inclusion. We screened all results initially, excluding over 313 records that were not relevant; with our second screening, 187 articles were assessed resulting in 24 full‐text articles fully assessed for eligibility. After further assessment, we found 12 potential studies eligible for inclusion. During the cross‐checking process however, two further studies were excluded; <a href="./references#CD010226-bbs2-0015" title="HamiltonM , HordernA , WaldropFN , LofftJ . A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment. British Journal of Psychiatry1963;109:510‐22. ">Hamilton 1963</a> and <a href="./references#CD010226-bbs2-0017" title="HuntPV . A comparison of the effects of oxypertine and trifluoperazine in withdrawn schizophrenics. British Journal of Psychiatry1967;113(505):1419‐24. [MEDLINE: 4865294] ">Hunt 1967</a> did not provide relevant data rendering them unusable, thus we were able to include only 10 studies (<a href="#CD010226-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010226-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010226-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010226-sec-0101"> <h5 class="title">2. Economic</h5> <p>We identified 15 potential studies in our economic evaluation search, none of which met our inclusion criteria for Type A and B. Twelve studies were excluded (See <a href="#CD010226-tbl-0003">Table 2</a>) and three are awaiting classification (See <a href="#CD010226-tbl-0004">Table 3</a>). See also <a href="#CD010226-fig-0002">Figure 2</a>. Had we found any studies of Type A or B quality, they would have been presented in <a href="#CD010226-tbl-0002">Table 1</a>. We therefore present data for Type C economic evaluation only. </p> <div class="figure" id="CD010226-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram: economic summary (2013)" data-id="CD010226-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: economic summary (2013)</p> </div> </div> </div> <div class="table" id="CD010226-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Economic studies: excluded</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for exclusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study type</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0034" title="DaviesLM , LewisS , JonesPB , BarnesTR , GaughranF , HayhurstK , et al. Cost‐effectiveness of first‐ v. second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry2007;191:14‐22. ">Davies 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: first vs second generation antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0043" title="FilippelliE , BiricoltiG , ScaranoC , RussoF , LucianoL . Treatment of psychotic disorders with olanzapine, risperidone and typical neuroleptics: a comparative cost‐effectiveness evaluation in a local psychiatric setting. Farmeconomia e Percorsi Terapeutici2005;6(3):161‐8. ">Filippelli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: atypical vs typical antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0045" title="GalvinPM , KnezekLD , RushAJ , TopracMG , JohnsonB . Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clinical Therapeutics1999;21(6):1105‐16. ">Galvin 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: not randomised.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0046" title="GhaemiSN , KirkwoodCK , SamburMR , KoJY , HowdenKL , DuongQ , et al. Economic outcomes of risperidone in comparison to typical neuroleptic agents for treatment‐resistant psychosis: a community‐based study. Journal of Pharmacy Technology2001;17:273‐8. ">Ghaemi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: not randomised.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0050" title="HanrahanP , LuchinsDJ , FabianR , TolleyG . Cost‐effectiveness of atypical antipsychotic medications versus conventional medication. Expert Opinion in Pharmacotherapy2006;7(13):1749‐58. ">Hanrahan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: atypical vs conventional antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0058" title="KnappM , WindmeijerF , BrownJ , KontodimasS , TzivelekisS , HaroJM , et al. Cost‐utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan‐European SOHO study. PharmacoEconomics2008;26(4):341‐58. ">Knapp 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: olanzapine vs other antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0064" title="LewisR . Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian Journal of Psychiatry1998;43(6):596‐604. ">Lewis 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0065" title="LewisSW , DaviesL , JonesPB , BarnesTRE , MurrayRM , KerwinR , et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment2006;10(17):1‐182. ">Lewis 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0069" title="MartinJL , PerezV , SacristanM , Rodriguez‐ArtalejoF , MartinezC , AlvarezE . Meta‐analysis of drop‐out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry2006;21(1):11‐20. ">Martin 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0073" title="MouldQJ , ContrerasHI , VerduzcoW , MejiaAJM , GardunoEJ . Cost‐effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics. Revista de Psiquiatrí́a y Salud Mental2009;2(3):108‐18. ">Mould 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: cost and effectiveness of ziprasidone, olanzapine, risperidone, haloperidol and clozapine (not trifluoperazine). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0084" title="StargardtT , WeinbrennerS , BusseR , JuckelG , GerickeCA . Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Journal of Mental Health Policy and Economics2008;11(2):89‐97. ">Stargardt 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: not randomised.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0085" title="SuttajitS , SrisurapanontM , ManeetonB , ManeetonN , SuttajitS . Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007815] ">Suttajit 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010226-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Economic studies: awaiting classification</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mapelli 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Awaiting classification.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full article not obtained.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mauskopf 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Awaiting classification.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full article not obtained.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percudani 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Awaiting classification.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full article not obtained.</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD010226-sec-0102"> <h4 class="title">Included studies</h4> <p>Further details of the 10 included studies in this review are provided in the <a href="./references#CD010226-sec-0228" title="">Characteristics of included studies</a>. </p> <p>We found no studies meeting our inclusion criteria for economic evaluation Types A and B. However, for Type C‐level evidence, we utilised the data from relevant economic outcomes of interest (relapse and hospital discharge) from three trials included in the effectiveness section of the systematic review (<a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>; <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>). </p> <section id="CD010226-sec-0103"> <h5 class="title">1. Length of studies</h5> <p>The duration of the studies included ranged from four weeks in <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>, through to seven months in <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>. The majority of the trials were between two and four months long, and in one study there was an additional observation trial period. In <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> the study lasted for 16 weeks with an additional 22‐week trial period that included some of the originally randomised participants. </p> </section> <section id="CD010226-sec-0104"> <h5 class="title">2. Clinical state</h5> <p>Participants in nine of the included studies were described as having chronic schizophrenia; however there were no diagnostic criteria described with this judgement (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964;</a><a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> and <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>) and one study described participants as having acute paranoid schizophrenia using the Bleuler Criteria (<a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>). </p> </section> <section id="CD010226-sec-0105"> <h5 class="title">3. Diagnosis</h5> <p>In nine of the included studies the diagnosis of all participants was schizophrenia (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>; <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>). Diagnosis of 14% of participants in <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>, however, was described as 'chronic psychotic'. We decided to include this study, as the vast majority of participants had schizophrenia, and the study investigated the effects of trifluoperazine on schizophrenia as its primary focus. </p> </section> <section id="CD010226-sec-0106"> <h5 class="title">4. Exclusions</h5> <p>Where exclusion criteria were listed, these often included physical or neurological disease, mental deficiency, epilepsy, organic brain disease and those who had been hospitalised for under two years (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>). <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a> excluded any patients who had history of renal or metabolic disease, people under the age of 18, and those suffering from central nervous system (CNS) syphilis. Additional exclusion criteria used in <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> were drug addictions and severe depression. <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> excluded any patients over the age of 55 years 'with a history of complicating organic factors'. </p> </section> <section id="CD010226-sec-0107"> <h5 class="title">5. Age</h5> <p>The range of ages of participants ranged from 18 years (<a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>), to 67 years (<a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>). Eight of the studies (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>; <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>) gave a mean value for the ages of participants with this ranging from 33.25 (<a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>) to 49 years (<a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>). However, the majority of the mean values were between 40 and 49 years. Only <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a> gave no data relating to age. </p> </section> <section id="CD010226-sec-0108"> <h5 class="title">6. Gender</h5> <p>In total there were n = 508 men and n = 402 women in the included studies. However, out of this number, there were only data available for n = 159 men and n = 108 women (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>; <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>). <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a> stated that men and women were "equally represented", and <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a> described male and female distribution as "comparable". <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> did not provide details of male/female distribution amongst groups. <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> was the only study to target only male participants. </p> </section> <section id="CD010226-sec-0109"> <h5 class="title">7. Study size</h5> <p>There were a total of n = 910 participants in the included studies; however, only n = 686 were relevant to this review after selecting data concerning only trifluoperazine or placebo, as some studies had additional treatment arms comparing other antipsychotic drugs. The study sizes varied from 34 participants (<a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>) to "approximately 360" participants (<a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>) with a mean of n = 90 participants between studies. Again, after selecting data from participants only relevant to our comparison, the range of study sizes varied from n = 23 to "approximately 360" participants, with a mean of n = 69 participants. </p> </section> <section id="CD010226-sec-0110"> <h5 class="title">8. Setting</h5> <p>Nine of the 10 included studies were conducted in a hospital setting, with the majority completed in the USA (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>; <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>), followed by Canada (<a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>; <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>) and India (<a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>). While <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> described the setting as a "rehabilitative half‐way house", again in the USA. </p> </section> <section id="CD010226-sec-0111"> <h5 class="title">9. Interventions</h5> <p>We were interested only in the populations that included trifluoperazine and placebo interventions. In most of the included studies there were comparisons to other drugs, which we did not utilise.<br/> The dose given of trifluoperazine ranged from a minimum of 5 mg a day (<a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>) through to a maximum high dose of 80 mg a day (<a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>). The mean of dose of all included studies was 30 mg/day. All included studies administered trifluoperazine and placebo in oral capsule form.<br/> <br/> Two studies implemented a fixed dose of 15 mg/day (<a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>); two studies increased the dose, starting from 5 mg/day increasing to 40 mg/day (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>. Two studies increased dosage over the duration of the study, from 10 mg/day to 50 mg/day (<a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>) and 20 mg/day to 40 mg/day (<a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>). One study reported a range of 10 mg/day to 50 mg/day (<a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>), while <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> reported a mean of 17.5 mg/day and <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a> a mean of 28 mg/day. <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> compared high‐dose trifluoperazine (80 mg/day) to low‐dose trifluoperazine (15 mg/day) with placebo ‐ the results of this particular study have been pooled and presented in the main comparison, as well as two separate comparisons in the data and analysis section. This was the only study to compare high and low doses, therefore meta‐analysis was not possible. </p> </section> <section id="CD010226-sec-0112"> <h5 class="title">10. Outcomes</h5> <p>Only binary data were available for outcomes, including: clinical improvement; severe short terms adverse effects; relapse; leaving the study early; use of anti‐Parkinson drugs. The majority of the included studies used a continuous rating scale to measure improvement; mental state; EPS and behaviour. However, with no statistical data available for use in meta‐analysis (often with only P values available), data were rendered usable. </p> <p>Rating scales used in included studies that provided dichotomised outcomes are listed below: </p> <p><b>10.1 Global state</b> </p> <p><i>10.1.1 Clinical global impression (CGI)</i> (<a href="./references#CD010226-bbs2-0049" title="GuyW , BonatoRR . Clinical Global Impressions. In: GuyW , BonatoRR editor(s). Manual for the ECDEU Assessment Battery. 2 Rev. National Institute of Mental Health, 1970:12‐1‐12‐6. ">Guy 1970</a>) </p> <p>The CGl enables clinicians to quantify the severity of symptoms of any mental health problem at one point in time. Clinicians are then able to measure any improvement or worsening of symptoms over time. A seven‐point scale is used, scoring from one (= very much improved) to seven (= very much worse). <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> and <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> used this scale to measure improvement, presented as a dichotomous outcome. </p> <p><i>10.1.2 Minnesota Multiphasic Personality Inventory (MMPI)</i> (<a href="./references#CD010226-bbs2-0051" title="HathawaySR , McKinleyJC . A multiphasic personality schedule (Minnesota): I. Construction of the schedule. Journal of Psychology1940;10:249‐54. ">Hathaway 1940</a>) </p> <p>The MMPI was originally developed in 1939, to assess personality traits and psychopathology, administered only by a psychologist specifically trained to do so. It has since been revised ‐ in 1989 (MMPI‐2), 1992 (MMPI‐2) and 2003 (MMPI‐2 RF). The 1939 scale used an empirical keying approach, which derived clinical scales by selecting items endorsed by patients known to have been diagnosed with certain pathologies. The later versions of this scale developed the use of sub scales, to allow for more accessible interpretation of results. The most recent scale consists of two sub scales with a total of 567 items; a clinical sub scale, which assesses 10 traits (including depression, hysteria, paranoia, schizophrenia, hypomania), as well as a validity sub scale, designed to test for inter‐rater reliability. <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> used this scale to measure improvement, presented as a dichotomous outcome. </p> <p><i>10.1.3 Manifest Behvaiour Scale (MBS)</i> (<a href="./references#CD010226-bbs2-0070" title="MendelsohnRM , PenmanAS , SchieleBC . Massive chlorpromazine therapy: the nature of behavioural changes. Psychiatric Quarterly1959;33(Jan):1‐22. ">Mendelsohn 1959</a>) </p> <p>This scale was designed to measure behavioural changes and consists of 90 items. The MBS subjectively measures the frequency of particular manifest behaviour items, such as 'does he talk to, or answer, what might be hallucinations?'; 'has frequent changes in mood'; 'combs his hair'; 'frequently has tantrums', with a higher score equalling a worsening in behaviour. <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> used this scale to measure improvement, presented as a dichotomous outcome. </p> <p><i>10.1.4 Quantification of Psychotic Symptom Severity (QPSS)</i> (<a href="./references#CD010226-bbs2-0047" title="GoodrichDW . Quantification of the severity of overt psychotic symptoms. American Journal of Psychiatry1953;110:334‐41. ">Goodrich 1953</a>) </p> <p>The QPSS is an observer‐rated scale, administered within a 15‐minute session, and intended to provide a simple, concise method of rating symptoms to aid hospital psychiatrists when rating severity of a psychotic illness. The scale, however, is not intended to "assess highly complex changes" or evaluate symptoms of non‐hospitalised people with a psychiatric illness. The scale consists of 28 items, dispersed into one of five categories, including: physical state; psychosomatic symptoms; behaviour; emotional state; and mental content items. The rater uses the accompanying 'criteria for quantitation of psychotic symptom severity' to measure the symptom between one (= most extreme degree of symptom) and four (= absence of the symptom), with a higher overall result indicating lower degree of behavioural disturbance and incapacity. <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a> used this scale to measure clinical improvement in global state, presented as a dichotomous outcome. </p> <p><b>10.2 Mental state</b> </p> <p><i>10.2.1 Psychotic Reaction Profile (PRP)</i> (<a href="./references#CD010226-bbs2-0066" title="LorrMO , O'ConnorJP , StaffordJW . The psychotic reaction profile. Journal of Clinical Psychology1960;16:241‐5. ">Lorr 1960</a>) </p> <p>The PRP was developed to document observable psychotic behaviour in a hospital setting, to be developed into a behaviour inventory for use by nurses and aides who have greater exposure and therefore greater opportunity to observe patients. The scale consists of 85 items, each categorised into one of four scales including withdrawal; thinking disorganisation; paranoid belligerence; and agitated depression. Items are answered with either 'true', 'false' or 'doesn't apply', with greater score indicating a worse outcome. <a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a> used this scale to measure improvement, presented as a dichotomous outcome. </p> <p><b>10.3 Behaviour</b> </p> <p><i>10.3.1 Miminal Social Behaviour Scale (MSBS)</i> (<a href="./references#CD010226-bbs2-0042" title="FarinaA , DavidA , GuskinS . A scale for measuring minimal social behaviour. Journal of Consultant Psychology1957;21:265‐8. ">Farina 1957</a>) </p> <p>The MSBS measures 32‐items using an environmental, subjective method; the scale is administered "in a room containing a desk, two chairs, a waste paper basket and nothing more". The rater and patient sit in the room; a set of dialogue and actions are then performed by the rater, in order to gauge the response of the patient ‐ for example, "5. The examiner says: 'won't you have a seat'" (to score one point if the patient is seated without further urging), with a higher score indicating a more favourable outcome. <a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a> used this scale to measure improvement, presented as a dichotomous outcome. </p> <p><i>10.3.2 Wings Behaviour Rating Scale (Wings)</i> (<a href="./references#CD010226-bbs2-0090" title="WingJK . A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science1961;107:862‐75. ">Wing 1961</a>) </p> <p>This scale consists of two sub scales; the first measures the mental state and four typical symptoms associated with schizophrenia in a brief interview on a five‐point scale. The second sub scale measures 12 behaviour items on a three‐point scale, with a higher score indicating a more acute state. <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a> used this scale to measure improvement in behaviour, presented as a dichotomous outcome. </p> </section> <section id="CD010226-sec-0113"> <h5 class="title">11. Missing outcomes</h5> <p>None of the included studies assessed economic outcomes or quality of life/satisfaction with care for either recipients or caregivers. Nor were there any deaths reported in any of the included studies. </p> </section> <section id="CD010226-sec-0114"> <h5 class="title">12. Funding</h5> <p><a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a> was supported by a Public Health Grant from the National Institute of Mental Health (USA), and <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> received various Public Health Service grants from the National Institute of Mental Health.<br/> Six of the 10 included studies were funded, at least in part, by pharmaceutical companies. <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a> received a grant from USPHS and a grant in‐aid from Lederle laboratories. <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> trial drugs provided by McNeil Laboratories. <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a> received study drugs from Smith, Kline &amp; French; and Merck, Sharp &amp; Dohme. <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a> received study drugs from Smith, Kline &amp; French; and Montreal &amp; Hoffman LaRoche. <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a> received trial drugs and 'financial assistance' from Ethnor Limited. Smith, Kline &amp; French also provided the study drugs and placebo in <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>. Funding was not stated in <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a> or <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>. </p> </section> </section> <section id="CD010226-sec-0115"> <h4 class="title">Excluded studies</h4> <p>In total we excluded 14 studies. Of these, six were not randomised (<a href="./references#CD010226-bbs2-0013" title="CahanRB . Efficacy of trifluoperazine in chronic mental illness. American Journal of Psychiatry1960;116:838. ">Cahan 1960</a>; <a href="./references#CD010226-bbs2-0018" title="LeffJP , WingJK . Trial of maintenance therapy in schizophrenia. British Medical Journal1971;3(775):599‐604. [MEDLINE: 4936538] ">Leff 1971</a>; <a href="./references#CD010226-bbs2-0021" title="MortonMR . A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia. American Journal of Psychiatry1968;124(11):1585‐8. [MEDLINE: 4869439] ">Morton 1968</a>; <a href="./references#CD010226-bbs2-0022" title="StanleyWJ , WaltonD . Trifluoperazine (stelazine). A controlled clinical trial in chronic schizophrenia. Journal of Mental Science1961;107:250‐7. ">Stanley 1961</a>; <a href="./references#CD010226-bbs2-0023" title="WeckowiczTE , WardTF . Clinical trial of 'stelazine' on apathetic chronic schizophrenics. Journal of Mental Science1960;106:1008‐15. ">Weckowicz 1960</a>; <a href="./references#CD010226-bbs2-0024" title='WestonFK , LoftusAP . A terminal double‐blind trial of tri‐fluoperazine ("stelazine") in chronic schizophrenia. Medical Journal of Australia1961;48(1):776‐80. [MEDLINE: 13784630] '>Weston 1961</a>). A further six did not yield any usable data ‐ one of these was a cross‐over design that did not present any data pre‐cross‐over (<a href="./references#CD010226-bbs2-0012" title='BarronA , BeckeringB , RudyLH , SmithJA . A "double‐blind" study comparing RO 4‐0403, trifluoperazine and a placebo in chronically ill mental patients. American Journal of Psychiatry1961;118:347‐8. '>Barron 1961</a>) while another was a withdrawal study, not yielding results for placebo (<a href="./references#CD010226-bbs2-0016" title="HoldenJ , ItilT , GannonP , KeskinerA . The clinical effects of intramuscular thiothixene and trifluoperazine in chronic schizophrenia: a comparative study. Current Therapeutic Research, Clinical and Experimental1971;13(5):298‐310. [MEDLINE: 71276382] ">Holden 1971</a>); the other four studies did not present any extractable data (<a href="./references#CD010226-bbs2-0011" title="AbuzzahabFS . The treatment of schizophrenia with long‐acting oral neuroleptics: a six‐month double‐blind investigation of penfluridol versus trifluoperazine. Psychopharmacology Bulletin1977;13(3):26‐7. [MEDLINE: 329326] ">Abuzzahab 1977</a>; <a href="./references#CD010226-bbs2-0015" title="HamiltonM , HordernA , WaldropFN , LofftJ . A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment. British Journal of Psychiatry1963;109:510‐22. ">Hamilton 1963</a>; <a href="./references#CD010226-bbs2-0017" title="HuntPV . A comparison of the effects of oxypertine and trifluoperazine in withdrawn schizophrenics. British Journal of Psychiatry1967;113(505):1419‐24. [MEDLINE: 4865294] ">Hunt 1967</a>; <a href="./references#CD010226-bbs2-0020" title="MadgwickJRA , McNeillDLM , DriverM , PrestonGC . Stelazine (trifluoperazine). A preliminary report on a clinical trial. Journal of Mental Science1958;104:1195‐8. ">Madgwick 1958</a>). <a href="./references#CD010226-bbs2-0019" title="LeffJP . Influence of selection of patients on results of clinical trials. British Medical Journal1973;4(5885):156‐8. [MEDLINE: 4584708] ">Leff 1973</a> pooled results from two RCTs, rendering data unusable. Due to the length of time that has elapsed since these studies were undertaken, the review authors were unable to contact trial authors in the pursuit of attaining further information where we classified data as 'unusable'. <a href="./references#CD010226-bbs2-0014" title="CoonsWH , BoydBA , WhiteJG . Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients. Canadian Psychiatric Association Journal1962;7:159‐63. ">Coons 1962</a> was excluded as participants were of mixed diagnosis, including participants who had received pre‐frontal lobotomy. </p> <p>Twelve economic studies were excluded altogether; this was due to no randomisation in three studies (<a href="./references#CD010226-bbs2-0045" title="GalvinPM , KnezekLD , RushAJ , TopracMG , JohnsonB . Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clinical Therapeutics1999;21(6):1105‐16. ">Galvin 1999</a>; <a href="./references#CD010226-bbs2-0046" title="GhaemiSN , KirkwoodCK , SamburMR , KoJY , HowdenKL , DuongQ , et al. Economic outcomes of risperidone in comparison to typical neuroleptic agents for treatment‐resistant psychosis: a community‐based study. Journal of Pharmacy Technology2001;17:273‐8. ">Ghaemi 2001</a>; <a href="./references#CD010226-bbs2-0084" title="StargardtT , WeinbrennerS , BusseR , JuckelG , GerickeCA . Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Journal of Mental Health Policy and Economics2008;11(2):89‐97. ">Stargardt 2008</a>), four results were in fact systematic reviews (<a href="./references#CD010226-bbs2-0064" title="LewisR . Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian Journal of Psychiatry1998;43(6):596‐604. ">Lewis 1998</a>; <a href="./references#CD010226-bbs2-0065" title="LewisSW , DaviesL , JonesPB , BarnesTRE , MurrayRM , KerwinR , et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment2006;10(17):1‐182. ">Lewis 2006</a>; <a href="./references#CD010226-bbs2-0069" title="MartinJL , PerezV , SacristanM , Rodriguez‐ArtalejoF , MartinezC , AlvarezE . Meta‐analysis of drop‐out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry2006;21(1):11‐20. ">Martin 2006</a>; <a href="./references#CD010226-bbs2-0085" title="SuttajitS , SrisurapanontM , ManeetonB , ManeetonN , SuttajitS . Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007815] ">Suttajit 2009</a>) and five studies did not present specific outcome measures for trifluoperazine (<a href="./references#CD010226-bbs2-0034" title="DaviesLM , LewisS , JonesPB , BarnesTR , GaughranF , HayhurstK , et al. Cost‐effectiveness of first‐ v. second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry2007;191:14‐22. ">Davies 2007</a>; <a href="./references#CD010226-bbs2-0043" title="FilippelliE , BiricoltiG , ScaranoC , RussoF , LucianoL . Treatment of psychotic disorders with olanzapine, risperidone and typical neuroleptics: a comparative cost‐effectiveness evaluation in a local psychiatric setting. Farmeconomia e Percorsi Terapeutici2005;6(3):161‐8. ">Filippelli 2005</a>; <a href="./references#CD010226-bbs2-0050" title="HanrahanP , LuchinsDJ , FabianR , TolleyG . Cost‐effectiveness of atypical antipsychotic medications versus conventional medication. Expert Opinion in Pharmacotherapy2006;7(13):1749‐58. ">Hanrahan 2006</a>; <a href="./references#CD010226-bbs2-0058" title="KnappM , WindmeijerF , BrownJ , KontodimasS , TzivelekisS , HaroJM , et al. Cost‐utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan‐European SOHO study. PharmacoEconomics2008;26(4):341‐58. ">Knapp 2008</a>; <a href="./references#CD010226-bbs2-0073" title="MouldQJ , ContrerasHI , VerduzcoW , MejiaAJM , GardunoEJ . Cost‐effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics. Revista de Psiquiatrí́a y Salud Mental2009;2(3):108‐18. ">Mould 2009</a>). See <a href="#CD010226-tbl-0003">Table 2</a>. </p> <section id="CD010226-sec-0116"> <h5 class="title">Studies awaiting classification</h5> <p><a href="./references#CD010226-bbs2-0025" title="Ortega‐SotoHA , BrunnerE , ApiquianR , de laTorreMP , UlloaRE . Typical antipsychotics: the threshold doses strategy. Proceedings of the 20th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1996 Jun 23‐27; Melbourne, Australia. 1996. ">Ortega‐Soto 1996</a> is available only as an abstract and we await the full paper. </p> <p>Three economic studies await classification, due to full reports not being obtainable at the time of writing (See <a href="#CD010226-tbl-0004">Table 3</a>). </p> </section> </section> </section> <section id="CD010226-sec-0117"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010226-fig-0003">Figure 3</a> and <a href="#CD010226-fig-0004">Figure 4</a> for a graphical overview. </p> <div class="figure" id="CD010226-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010226-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010226-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010226-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010226-sec-0118"> <h4 class="title">Allocation</h4> <p>We excluded any studies that involved no random element as we felt that these would introduce potential for bias in our outcome results. All of the included studies were either described as randomised or implied randomisation in their allocation. Only one of the included trials gave a method of randomisation, with Lederle Laboratories providing a random block for the allocation of the drugs (<a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>); this was the only study to be rated as a 'low' risk of bias. None of the other included studies mentioned a method of randomisation but instead described 'random allocation', 'random assignment', or 'random division' to groups. For this reason, the remaining nine studies were rated as an 'unclear' risk of bias. </p> <p>The majority of studies gave no details as to allocation concealment and were therefore rated as an 'unclear' risk; only one study provided details, in which allocation was controlled by the pharmacy, withholding allocation from investigators (<a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>). This is the only study to be rated as a 'low' risk of bias. </p> </section> <section id="CD010226-sec-0119"> <h4 class="title">Blinding</h4> <p>All but one of the 10 included studies were described as 'double blind', with a single study implied using a single (assessor) blind method (<a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>), with no details of participant blinding. This study was rated as an 'unclear risk'. Of the remaining nine studies, a double blind code was mentioned but not described (<a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>), or identical capsules for all of the groups to prevent appearance of the drugs weakening the blinding, with no further detail as to assessor blinding (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>). Although, in a trial of this nature, it can be said that blinding would have been difficult to maintain and more prone to being broken due to the extrapyramidal side effects that the trifluoperazine manifests. In longer trials, the patients in the placebo group would also have a greater likelihood of global worsening as they were not receiving any active medication.<br/> <br/> Distribution of medication was controlled by the pharmacy in <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>, stating that ward personnel and participants were unaware of the medication they received. <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a> described a large effort for blinding throughout the course of the study, however blinding seemed to have been broken in the second phase of the study. For these reasons, these studies were rated with an 'unclear' risk of bias. Only <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> described strict double blind conditions in which capsules identical in appearance were used, and only the hospital pharmacist had the code ‐ for this reason, we decided to rate this study as a 'low' risk of bias. </p> </section> <section id="CD010226-sec-0120"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies were rated as 'low' risk by the review authors, who reported either no loss to follow‐up or drop‐outs at any point (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>), or participant drop‐outs due to adverse effects, but making use of intention‐to‐treat (ITT) (<a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>). For the one of the three studies rated as 'unclear', no drop‐outs were reported throughout the trial period (<a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>), but due to no explicit mention of all participants completing the entire study duration, this study was rated as an 'unclear' risk. For the remaining, drop‐outs were reported either due to 'strong drug reactions', going 'AWOL', or other adverse effects, but it remains unclear how participant data were handled and to what extent ITT were used, if at all (<a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>).<br/> <br/> The remaining studies were all rated as a 'high' risk; either because drop‐out rates were reported with reasons but without use of ITT (<a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>); or participants were excluded from the investigation after being assigned to electroconvulsive therapy (ECT) or transferring/home leave (<a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>). Only half of the participants in each intervention group in <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> were tested using specified rating scales throughout the course of the study, while the remaining participants were termed "untestable" and not included in analysis. Finally, <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> has been starred because the trial authors gave only an approximation of randomised participants included in the study, with group numbers varying between outcomes ‐ therefore, we found it hard to identify the true number of participants that left early or that were included in the final analysis. This particular study was subject to a sensitivity analysis. </p> </section> <section id="CD010226-sec-0121"> <h4 class="title">Selective reporting</h4> <p>None of the included studies provided protocol information, making it difficult to ascertain any explicit selective reporting. With the data available to us, however, we found that each included study used a continuous rating scale to measure either mental state (including the BPRS or PANSS), global state (CGI), behaviour (NOSIE) as well as other scales to rate EPS and social functioning. However, none of the included studies provided usable continuous data; for instance, only providing only P values; means with no standard deviations and, in the majority of studies, only graphs and visual representations were available for inspection. For this reason, six of the included studies were rated as a 'unclear' risk under this category (<a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>; <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>), while the remaining four studies were rated as a 'high' risk where outcomes expressed in the methods sections were not reported (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>), or where methods of analysis were changed retrospectively upon completion of the study (<a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>). </p> </section> <section id="CD010226-sec-0122"> <h4 class="title">Other potential sources of bias</h4> <p>Six of the 10 included studies were funded, at least in part, by pharmaceutical companies. <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a> received a grant from USPHS and a grant in‐aid from Lederle laboratories. <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> trial drugs provided by McNeil Laboratories. <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a> received study drugs from Smith, Kline &amp; French; and Merck, Sharp &amp; Dohme. <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a> received study drugs from Smith, Kline &amp; French; and Montreal &amp; Hoffman LaRoche. <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a> received trial drugs and 'financial assistance' from Ethnor Limited. Smith, Kline &amp; French also provided the study drugs and placebo in <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>.<br/> <br/> Four of the included studies explicitly stated that raters were independent of treatment (<a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>; <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>), however, we decided to keep these ratings as an 'unclear' risk because three of these studies were funded, at least in part, by a pharmaceutical company, and the primary investigator in <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> was also the author of the MBS scale, administered to measure their primary outcome of improvement.<br/> <br/> We rated only one study (<a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>) as a 'high' risk of bias, in which the trials authors acknowledged that the social worker administering the social rating scale was “prejudiced by the nature of her job” by working at the 'half‐way house' in which the study was undertaken. This study also received trial drugs from McNeil Laboratories Inc.<br/> <br/> Another potential source of bias in these studies was the general small sample size; for instance, six studies have 40 or less participants relevant to our review, these include <a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a> and <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>. </p> </section> </section> <section id="CD010226-sec-0123"> <h3 class="title" id="CD010226-sec-0123">Effects of interventions</h3> <p>See: <a href="./full#CD010226-tbl-0001"><b>Summary of findings for the main comparison</b> TRIFLUOPERAZINE versus PLACEBO for schizophrenia</a> </p> <p>Only dichotomous data were found; we used risk ratios (RR) with 95% confidence intervals (CIs) throughout. </p> <section id="CD010226-sec-0124"> <h4 class="title">1. TRIFLUOPERAZINE versus PLACEBO</h4> <p>All studies provided data for this comparison (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a>; <a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>; <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>) with a total of n = 910. </p> <section id="CD010226-sec-0125"> <h5 class="title">1.1 Global state: clinical improvement</h5> <p>Overall, there was a highly significant improvement in clinical state in the trifluoperazine group (6 RCTs, n = 509, RR 6.44, CI 2.72 to 15.22) as well as significant clinical improvements in both sub‐categories in the short term (zero to three months) (3 RCTs, n = 92, RR 10.93, CI 2.74 to 43.60) and medium term (three to six months) favouring trifluoperazine (3 RCTs, n = 417, RR 4.61, CI 1.54 to 13.84, <a href="./references#CD010226-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD010226-sec-0126"> <h5 class="title">1.2 Behaviour: clinically significant agitation or distress (as defined by each study)</h5> <p><a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a> was the only study to give usable data on agitation and found no significant difference between the two groups in the short/medium term (1 RCT, n = 52, RR 2.00, CI 0.19 to 20.72, <a href="./references#CD010226-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD010226-sec-0127"> <h5 class="title">1.3 Behaviour: use of adjunctive medication for sedation</h5> <p>Data were equivocal at medium term (1 RCT, n = 50, RR 0.94, CI 0.34 to 2.61) and long term (1 RCT, n = 50, RR 0.80, CI 0.24 to 2.61, <a href="./references#CD010226-fig-0007" title="">Analysis 1.3</a>) in the one study that reported this outcome. </p> </section> <section id="CD010226-sec-0128"> <h5 class="title">1.4 Behaviour: clinical improvement</h5> <p>One small study found significant clinical improvement in the short term in the trifluoperazine group compared with placebo (1 RCT, n = 40, RR 27.00, CI 1.71 to 425.36, <a href="./references#CD010226-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010226-sec-0129"> <h5 class="title">1.5 Mental state: clinically significant response in psychotic symptoms</h5> <p>Meta‐analysis revealed no significant differences in 'intensified' psychotic symptoms between the two groups (4 RCTs, n = 139, RR 0.75, CI 0.32 to 1.74); however, there was slight heterogeneity present (P = 0.27; I<sup>2</sup> = 24%). No significance was shown in either the short term (2 RCTs, n = 59, RR 0.37, CI 0.09 to 1.58, again displaying slight heterogeneity; P = 0.25; I<sup>2</sup>= 25%), or by short/medium term (2 RCTs, n = 80, RR 1.05, CI 0.54 to 2.05, <a href="./references#CD010226-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD010226-sec-0130"> <h5 class="title">1.6 Mental state: clinically significant response in positive symptoms</h5> <p>One small study showed no difference in significant clinical response (defined as 'delusions and hallucinations' in the particular study) in favour of the trifluoperazine group (1 RCT, n = 16, RR 0.17, CI 0.03 to 1.09, <a href="./references#CD010226-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD010226-sec-0131"> <h5 class="title">1.7 Leaving the study early: any reason</h5> <p>No significant difference was shown between the two groups in terms of leaving the study early for any reason (8 RCTs, n = 613, RR 0.72, CI 0.45 to 1.16, <a href="./references#CD010226-fig-0011" title="">Analysis 1.7</a>), over any time frame. There was considerable heterogeneity evident at medium term however, (2 RCTs, n = 391, RR 0.80, CI 0.17 to 3.81; P = 0.04; I<sup>2</sup> = 77%). It must be noted that leaving the study early for any reason across all time frames carried moderate heterogeneity (P = 0.15; I<sup>2</sup> = 35%). </p> </section> <section id="CD010226-sec-0132"> <h5 class="title">1.8 Leaving the study early: severe adverse effects</h5> <p>No difference was found overall (7 RCTs, n = 590, RR 1.00, CI 0.62 to 1.62), nor between groups in either short term (2 RCTs, n = 67, RR 1.31, CI 0.22 to 7.80), short/medium term (3 RCTs, n = 132, RR 0.84, CI 0.46 to 1.52) and medium term (2 RCTs, n = 391, RR 1.54, CI 0.56 to 4.24, <a href="./references#CD010226-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD010226-sec-0133"> <h5 class="title">1.9 Leaving the study early: due to relapse or worsening</h5> <p>In the meta‐analysis, there was a significant favour for trifluoperazine, with higher numbers of people leaving the study in the placebo groups (3 RCTs, n = 404, RR 0.35, CI 0.25 to 0.50), with significant difference shown at medium term (2 RCTs, n = 381, RR 0.34, CI 0.23 to 0.49) but no difference by short term (1 RCT, n = 23, RR 0.73, CI 0.15 to 3.57, <a href="./references#CD010226-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD010226-sec-0134"> <h5 class="title">1.10 Extrapyramidal adverse effects: general</h5> <p>Overall, there were significantly fewer general extrapyramidal adverse effects in the placebo group compared with trifluoperazine (5 RCTs, n = 184, RR 2.93, CI 1.28 to 6.70), however with slight heterogeneity (P = 0.14; I<sup>2</sup>= 48%). This high significance was shown to be present in the sub category of short term (3 RCTs, n = 92, RR 4.89, CI 1.36 to 17.59), but not in short/medium term (2 RCTs, n = 92, RR 2.08, CI 0.86 to 5.02, <a href="./references#CD010226-fig-0014" title="">Analysis 1.10</a>), which also demonstrated slight heterogeneity (P = 0.17; I<sup>2</sup>= 48%). </p> </section> <section id="CD010226-sec-0135"> <h5 class="title">1.11 Extrapyramidal adverse effects: use of antiParkinson drugs</h5> <p>Overall, significantly more patients required anti‐Parkinson drugs in the trifluoperazine group compared with the placebo group (3 RCTs, n = 114, RR 5.91, CI 2.64 to 13.26). This significance was demonstrated in the short/medium term (1 RCT, n = 40, RR 4.50, CI 1.11 to 18.27) and long term (1 RCT, n = 50, RR 8.50, CI 2.78 to 25.97) but not in the short term alone (1 RCT, n = 24, RR 3.00, CI 0.36 to 24.92, <a href="./references#CD010226-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD010226-sec-0136"> <h5 class="title">1.12 Extrapyramidal adverse effects: dyskinesia</h5> <p>Meta‐analysis revealed no difference in instances of dyskinesia in the short term (2 RCTs, n = 52, RR 3.00, CI 0.33 to 27.11, <a href="./references#CD010226-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD010226-sec-0137"> <h5 class="title">1.13 Extrapyramidal adverse effects: akathisia</h5> <p>Akathisia was shown to be highly significant with more prevalence in the trifluoperazine group, consequently favouring placebo (2 RCTs, n = 369, RR 10.78, CI 3.06 to 37.99). Short‐term data were not significant (1 RCT, n = 28, RR 5.00, CI 0.26 to 95.61), but slightly favouring the placebo group. Short/medium term data (zero to six months) were significant (1 RCT, n = 341, RR 12.79, CI 3.17 to 51.53, <a href="./references#CD010226-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD010226-sec-0138"> <h5 class="title">1.14 Extrapyramidal adverse effects: Parkinsonism</h5> <p>Instances of Parkinsonism were generally higher with those receiving trifluoperazine, however significance was found only by the short/medium term (1 RCT, n = 341, RR 1.93, CI 1.19 to 3.12). The finding was not significant at short term (2 RCTs, n = 44, RR 15.00, CI 0.94 to 239.81), nor in meta‐analysis of subgroups (3 RCTs, n = 385, RR 3.43, CI 0.54 to 21.69, <a href="./references#CD010226-fig-0018" title="">Analysis 1.14</a>). </p> </section> <section id="CD010226-sec-0139"> <h5 class="title">1.15 Extrapyramidal adverse effects: dystonia</h5> <p>There was no difference by the short/medium term (1 RCT, n = 341, RR 1.75, CI 0.94 to 3.29, <a href="./references#CD010226-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD010226-sec-0140"> <h5 class="title">1.16 Other adverse effects: general</h5> <p>Overall, all other adverse effects showed to be just non‐significant and slightly in favour of the placebo group, with more people receiving trifluoperazine showing more adverse effects (5 RCTs, n = 192, RR 1.90, CI 0.77 to 4.70), however, heterogeneity was considerable (P = 0.03; I<sup>2</sup> = 62%). Results were homogenous at short term, favouring placebo (2 RCTs, n = 68, RR 13.98, CI 1.94 to 100.64), and again by medium term (1 RCT, n = 44, RR 2.38, CI 0.37 to 15.16). However, in the short/medium term group, there was no difference (2 RCTs, n = 80, RR 1.10, CI 0.61 to 2.00, <a href="./references#CD010226-fig-0020" title="">Analysis 1.16</a>), with heterogeneity evident again (P = 0.19; I<sup>2</sup> = 43%). </p> </section> <section id="CD010226-sec-0141"> <h5 class="title">1.17 Other adverse effects: specific</h5> <p>It was found that more participants receiving placebo experienced decreased appetite in the short/medium term in the placebo group (2 RCTs, n = 381, RR 0.59, CI 0.39 to 0.89). Results were also significant for rigidity, with more participants receiving trifluoperazine experiencing rigidity in the short/medium term (1 RCT, n = 40, RR 9.00, CI 1.25 to 64.59). </p> <p>Although not significant, dizziness (1 RCT, n = 341, RR 9.21, CI 0.54 to 156.86) and drowsiness (1 RCT, n = 24, RR 7.00, CI 0.40 to 122.44) appeared more frequently in the trifluoperazine group between zero to 6 months. Higher instances of oculogyric crisis were shown in the trifluoperazine group at short term (1 RCT, n = 24, RR 3.00, CI 0.13 to 67.06) and blurred vision in the short/medium term (2 RCTs, n = 92, RR 5.00, CI 0.26 to 98.00); furthermore, incoordination occurred more frequently in the trifluoperazine group (1 RCT, n = 40, RR 3.50, CI 0.83 to 14.83, <a href="./references#CD010226-fig-0021" title="">Analysis 1.17</a>). </p> </section> <section id="CD010226-sec-0142"> <h5 class="title">1.18 Other adverse effects: laboratory data</h5> <p>All data for laboratory tests were equivocal, for instance, with only slightly more people receiving trifluoperazine reported as either having lost weight (1 RCT, n = 24, RR 2.00, CI 0.45 to 8.94) or gained weight (1 RCT, n = 24, RR 2.00, CI 0.21 to 19.23, <a href="./references#CD010226-fig-0022" title="">Analysis 1.18</a>) at short term. </p> </section> <section id="CD010226-sec-0143"> <h5 class="title">1.19 Hospital and service utilisation outcomes: hospital transfer/home leave</h5> <p>There was no difference in the number of people either transferring hospitals or experiencing home leave (1 RCT, n = 23, RR 1.09, CI 0.08 to 15.41, <a href="./references#CD010226-fig-0023" title="">Analysis 1.19</a>). </p> </section> <section id="CD010226-sec-0144"> <h5 class="title">1.20 Hospital and service utilisation outcomes: hospital discharge</h5> <p>There was a slight favouring for trifluoperazine with this outcome, with more persons discharged compared with people receiving placebo in the medium term (1 RCT, n = 40, RR 3.00, CI 0.13 to 69.52, <a href="./references#CD010226-fig-0024" title="">Analysis 1.20</a>). </p> </section> <section id="CD010226-sec-0145"> <h5 class="title">1.21 Economic outcomes</h5> <p><b>Cost of adjunctive medication for sedation</b> </p> <p>The clinical assumption used was based on unit costs of phenobarbital (60 mg, 28‐tab pack = £5.75, BNF) and a 14‐day treatment period at 120 mg at night‐time per patient, per day. We synthesised estimates of differences in resource use by using relative risk as a proxy measure (see <a href="#CD010226-tbl-0005">Table 4</a>). The relative risk was 0.8(0.24,2.61) and using this the GBP value obtained for trifluoperazine was £4.6(1.38,15.0) as compared to £5.75 for placebo </p> <div class="table" id="CD010226-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Economic: Differences in resource use using Relative Risk (RR)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Resource</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Base case</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Favouring trifluoperazine (CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Favouring placebo (CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>RR</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Trifluoperazine</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Placebo</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>RR</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Trifluoperazine</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Placebo</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>RR</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Trifluoperazine</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Placebo</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjunctive medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of anti‐parkinson drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£25.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£11.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£57.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment for akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£8.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£2.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£30.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£2704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5408</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1930.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5418.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1367.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5418.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£2806.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5418.86</p> </td> </tr> </tbody> </table> </div> <p><b>Cost of anti‐parkinson medication</b> </p> <p>The clinical assumption used was based on unit costs (5 mg, net price 28‐tab pack = £1.44, BNF) and a 14‐day treatment period at 10 mg three times a day, per patient. We synthesised estimates of differences in resource use by using relative risk as a proxy measure. The relative risk was 5.91(2.64,13.25) and using this the GBP value obtained was £25.53(11.40,57.24) as compared to £4.32 for placebo </p> <p><b>Cost for treatment of akathisia</b> </p> <p>The clinical assumption used was based on unit costs (80 mg, 56‐tab pack = £1.57, BNF) and a 14‐day treatment period at 80 mg twice a day, per patient. We synthesised estimates of differences in resource use by using relative risk as a proxy measure. The relative risk was 10.78(3.06,37.99) and using this the GBP value obtained was £4.6(1.38,15.0) as compared to £0.79 for placebo </p> <p><b>Cost of relapse</b> </p> <p>This assumption was based on the HES‐calculated median length of hospital stay of 16 days (<a href="./references#CD010226-bbs2-0053" title="Hospital Episode Statistics, Admitted Patient Care ‐ England 2011‐12: Main Specialties (.xls). http://www.hscic.gov.uk/searchcatalogue?productid=9161&amp;q=title%3a%22hospital+episode+statistics%22&amp;sort=Relevance&amp;size=10&amp;page=1#top (accessed May 2013) 2011‐12. ">HES 2012</a>) multiplied by the PSSRU‐calculated mean daily cost of hospitalisation of £338 (<a href="./references#CD010226-bbs2-0077" title="Compiled by LesleyCurtis . Unit costs of health and social care 2012. http://www.pssru.ac.uk/project‐pages/unit‐costs/2012/ (accessed May 2013)2012:47. ">PSSRU 2012</a>). We synthesised estimates of differences in resource use by using relative risk as a proxy measure. The relative risk was 0.35(0.25,0.50) and using this the GBP value obtained was £1892(1352,2704) as compared to £5408 for placebo. </p> <p><b>Total: comparative savings</b> </p> <p>Our calculations show that there is a cost‐saving of £3488.3, when comparing placebo as against trifluoperazine, and most of these savings are due to an increase in relapse costs. Even using confidence intervals (95% CI) of effectiveness data, we still have savings of at least £2,612.6 in favour of trifluoperazine when using the upper‐end of the CI, which could go up to £4051.9 if using the lower‐end of the CI. </p> </section> </section> <section id="CD010226-sec-0146"> <h4 class="title">2. TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO</h4> <p>Only one study provided data for this comparison (<a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>), therefore meta‐analysis was not possible (n = 224). The low dose of trifluoperazine employed in this study was 15 mg/day. We decided to present the data for this study separately due to the incredibly high dose of trifluoperazine employed in the high dose group (80 mg a day). </p> <section id="CD010226-sec-0147"> <h5 class="title">2.1 Global state: clinical improvement</h5> <p>There was significantly greater (P = 0.04) improvement amongst people receiving low dose trifluoperazine at medium term than placebo (1 RCT, n = 220, RR 4.73, CI 1.06 to 21.11, <a href="./references#CD010226-fig-0025" title="">Analysis 2.1</a>). </p> </section> <section id="CD010226-sec-0148"> <h5 class="title">2.2 Leaving the study early: any reason</h5> <p>Significantly more people receiving placebo left the study early due to any reason by medium term (1 RCT, n = 224, RR 0.39, CI 0.25 to 0.60, <a href="./references#CD010226-fig-0026" title="">Analysis 2.2</a>). </p> </section> <section id="CD010226-sec-0149"> <h5 class="title">2.3 Leaving the study early: severe adverse effects</h5> <p>There was no difference in the amount of people leaving the study due to severe adverse effects by medium term (1 RCT, n = 224, RR 0.33, CI 0.03 to 3.10, <a href="./references#CD010226-fig-0027" title="">Analysis 2.3</a>). </p> </section> <section id="CD010226-sec-0150"> <h5 class="title">2.4 Leaving the study early: due to relapse or worsening</h5> <p>Significantly more people receiving placebo left the study early due to relapse or worsening by medium term (1 RCT, n = 224, RR 0.39, CI 0.25 to 0.61, <a href="./references#CD010226-fig-0028" title="">Analysis 2.4</a>). </p> </section> <section id="CD010226-sec-0151"> <h5 class="title">2.5 Extrapyrimidal adverse effects: akathisia</h5> <p>There were significantly greater instances of akathisia experienced by people receiving the low dose trifluoperazine (1 RCT, n = 224, RR 6.88, CI 1.60 to 29.56, <a href="./references#CD010226-fig-0029" title="">Analysis 2.5</a>). </p> </section> <section id="CD010226-sec-0152"> <h5 class="title">2.6 Extrapyrimidal adverse effects: Parkinsonism</h5> <p>There was no difference in Parkinsonism events between groups (1 RCT, n = 224, RR 0.69, CI 0.35 to 1.38, <a href="./references#CD010226-fig-0030" title="">Analysis 2.6</a>). </p> </section> <section id="CD010226-sec-0153"> <h5 class="title">2.7 Extrapyrimidal adverse effects: dystonia</h5> <p>There was no difference in dystonia events between groups (1 RCT, n = 224, RR 0.98, CI 0.44 to 2.17, <a href="./references#CD010226-fig-0031" title="">Analysis 2.7</a>). </p> </section> <section id="CD010226-sec-0154"> <h5 class="title">2.8 Other adverse effects: specific</h5> <p>Again, there was little difference in levels of specific adverse effects between groups; with slightly higher instances amongst people receiving trifluoperazine of effects such as fainting (1 RCT, n = 224, RR 4.91, CI 0.58 to 41.37); dizziness and fainting (1 RCT, n = 224, RR 6.88, CI 0.36 to 131.62) and hypotension (1 RCT, n = 224, RR 1.47, CI 0.79 to 2.75), however, this was not significant. Only higher instances of decreased appetite were shown in the placebo group, demonstrating statistical significance (1 RCT, n = 224, RR 0.60, CI 0.36 to 1.00, <a href="./references#CD010226-fig-0032" title="">Analysis 2.8</a>). </p> </section> </section> <section id="CD010226-sec-0155"> <h4 class="title">3. TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO</h4> <p>Only one study used a fixed high dose throughout the duration of the entire study (<a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>), therefore meta‐analysis was not possible (n = 228). The high dose of trifluoperazine employed in this study was 80 mg/day. </p> <section id="CD010226-sec-0156"> <h5 class="title">3.1 Global state: clinical improvement</h5> <p>Slightly more people receiving high‐dose trifluoperazine demonstrated improvement, however this was not a statistically significant finding (1 RCT, n = 228, RR 1.42, CI 0.52 to 3.87, <a href="./references#CD010226-fig-0033" title="">Analysis 3.1</a>). </p> </section> <section id="CD010226-sec-0157"> <h5 class="title">3.2 Leaving the study early: any reason</h5> <p>Significantly more people from the placebo group left the study early for 'any reason' (1 RCT, n = 228, RR 0.45, CI 0.30 to 0.67, <a href="./references#CD010226-fig-0034" title="">Analysis 3.2</a>). </p> </section> <section id="CD010226-sec-0158"> <h5 class="title">3.3 Leaving the study early: severe adverse effects</h5> <p>More people from the trifluoperazine group left the study early owing to severe adverse effects; however this was not a statistically significant finding (1 RCT, n = 228, RR 2.85, CI 0.79 to 10.24, <a href="./references#CD010226-fig-0035" title="">Analysis 3.3</a>). </p> </section> <section id="CD010226-sec-0159"> <h5 class="title">3.4 Leaving the study early: due to relapse or worsening</h5> <p>Significantly more people receiving placebo left the study early due to 'deteriorated behaviour' (1 RCT, n = 228, RR 0.28, CI 0.17 to 0.48, <a href="./references#CD010226-fig-0036" title="">Analysis 3.4</a>). </p> </section> <section id="CD010226-sec-0160"> <h5 class="title">3.5 Extrapyrimidal adverse effects: akathisia</h5> <p>Significantly more people who received trifluoperazine experienced akathisia than people receiving placebo (1 RCT, n = 228, RR 18.50, CI 4.58 to 74.80, <a href="./references#CD010226-fig-0037" title="">Analysis 3.5</a>). </p> </section> <section id="CD010226-sec-0161"> <h5 class="title">3.6 Extrapyrimidal adverse effects: Parkinsonism</h5> <p>There was slight favour for placebo by short/medium term, however this was not statistically significant (1 RCT, n = 228, RR 3.13, CI 1.94 to 5.03, <a href="./references#CD010226-fig-0038" title="">Analysis 3.6</a>). </p> </section> <section id="CD010226-sec-0162"> <h5 class="title">3.7 Extrapyrimidal adverse effects: dystonia</h5> <p>There were significantly higher instances of dystonia amongst people receiving high dose trifluoperazine by short/medium term (1 RCT, n = 228, RR 2.50, CI 1.31 to 4.76, <a href="./references#CD010226-fig-0039" title="">Analysis 3.7</a>). </p> </section> <section id="CD010226-sec-0163"> <h5 class="title">3.8 Other adverse effects: specific</h5> <p>A greater number of people taking placebo experienced decreased appetite by short/medium term (1 RCT, n = 228, RR 0.58, CI 0.35 to 0.97) with only slight statistical significance (P = 0.04).There were slightly higher instances of dizziness/faintness (1 RCT, n = 228, RR 12.34, CI 0.70 to 216.49); drowsiness (1 RCT, n = 228, RR 2.21, CI 0.88 to 5.56) and fainting (1 RCT, n = 228, RR 1.90, CI 0.17 to 20.63, <a href="./references#CD010226-fig-0040" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD010226-sec-0164"> <h4 class="title">4. Sensitivity analysis</h4> <section id="CD010226-sec-0165"> <h5 class="title">4.1 Implication of randomisation</h5> <p>All included studies at least stated that they used random allocation of participants to treatment.  However, no study mentions the procedure or type of randomisation apart from <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>. When all studies that did not provide adequate details of randomisation techniques were excluded from the analysis of our primary outcomes, the following changes were noted. </p> <section id="CD010226-sec-0166"> <h6 class="title">4.1.1 Global state: any clinically significant response in medium term global state (as defined by each study) </h6> <p>There were no longer significant levels of improvement among people taking trifluoperazine, with only the one study providing any data at the short term (1 RCT, n = 24, RR 6.00, CI 0.85 to 42.59). </p> </section> <section id="CD010226-sec-0167"> <h6 class="title">4.1.2 Behaviour: any clinically significant agitation or distress as defined by each study </h6> <p>As a result of removing the single study that measured this outcome with a rating of 'unclear' risk of bias associated with unclear randomisation techniques, there were no data left to compare. </p> </section> <section id="CD010226-sec-0168"> <h6 class="title">4.3.3 Severe adverse effects: any clinically significant severe short term adverse effects based on relevant rating scales </h6> <p>Data reported for people leaving the study early due to severe adverse effects at short term were only available after removing studies that were unclear as to randomisation. The results remain largely equivocal, but removed the slight heterogeneity that was found in the meta‐analysis (1 RCT, n = 24, RR 5.00, CI 0.27 to 94.34). </p> </section> <section id="CD010226-sec-0169"> <h6 class="title">4.1.4 Relapse +/‐ hospitalisation: relapse including any hospitalisation of a participant within a study </h6> <p>Again, data were reported for people leaving the study early due to relapse; after 'unclear' risk studies were removed from the analysis, there were no data left to compare. </p> </section> </section> <section id="CD010226-sec-0170"> <h5 class="title">4.2 Assumptions for lost binary data</h5> <p>We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention‐to‐treat (ITT) analysis using the above assumptions. </p> <section id="CD010226-sec-0171"> <h6 class="title">4.2.1 Global state: any clinically significant response in medium term global state (as defined by each study) </h6> <p>At short term, when comparing completer‐only data, data remain extremely significant, but with greater favour for trifluoperazine than when using ITT data (3 RCTs, n = 88, RR 11.97, CI 3.04 to 47.16). Data by medium term remain significant, but with a lower P value (P = 0.02 instead of P = 0.006) (3 RCTs, n = 300, RR 3.59, CI 1.21 to 10.67), with meta‐analysis of both short‐ and medium‐term subgroups still in significant favour of trifluoperazine (6 RCTs, n = 388, RR 5.72, CI 2.44 to 13.43). </p> </section> <section id="CD010226-sec-0172"> <h6 class="title">4.2.2 Behaviour: any clinically significant agitation or distress as defined by each study </h6> <p>Completer‐only data remain equivocal (1 RCT, n = 47, RR 1.92, CI 0.19 to 19.73).</p> </section> <section id="CD010226-sec-0173"> <h6 class="title">4.2.3 Severe adverse effects: any clinically significant severe short term adverse effects based on relevant rating scales </h6> <p>As per our protocol, those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and <i>adverse effects</i>, therefore we did not complete a sensitivity analysis comparing how likely the results are to change when compared with completer‐only data, as this would have the effect of unfairly over‐estimating the amount of severe adverse effects witnessed in any one arm of the study. </p> </section> <section id="CD010226-sec-0174"> <h6 class="title">4.2.4 Relapse +/‐ hospitalisation: relapse including any hospitalisation of a participant within a study </h6> <p>There is little difference in numbers of people leaving the studies early due to relapse when completer‐only data are used, however results display greater significance for trifluoperazine at short term (1 RCT, n = 16, RR 0.67, CI 0.15 to 2.98), medium term (2 RCTs, n = 280, RR 0.22, CI 0.16 to 0.30) and at both short and medium term together (3 RCTs, n = 296, RR 0.24, CI 0.16 to 0.37). </p> </section> </section> <section id="CD010226-sec-0175"> <h5 class="title">4.3 Risk of bias</h5> <p>Nine out of 10 studies were rated as a high risk of bias across one of the risk of bias domains for any of the primary outcomes (with <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a> as the only exception), including incomplete outcome data (attrition bias); selective reporting (reporting bias); and other bias. Nine out of 10 studies were also rated as an 'unclear' risk of bias under the randomisation factor (again, with <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a> as the only exception) and, no study was rated as a 'high' risk of bias for either allocation concealment (selection bias), nor blinding of participants or personnel (performance bias) when assessing our primary outcomes, which are listed as follows: </p> <section id="CD010226-sec-0176"> <h6 class="title">4.3.1 Global state: any clinically significant response in medium term global state (as defined by each study) </h6> <p>After removing studies rated as a 'high' risk of bias for incomplete outcome data (attrition bias) from the meta‐analysis, the results still favoured trifluoperazine at medium term for greater levels of improvement, however the results are no longer statistically significant, with much wider confidence intervals and far less power resulting from excluding the larger studies (1 RCT, n = 40, RR 3.00, CI 0.13 to 69.52). </p> </section> <section id="CD010226-sec-0177"> <h6 class="title">4.3.2 Behaviour: any clinically significant agitation or distress as defined by each study </h6> <p>As a result of removing the single study that measured this outcome with a rating of 'high' risk of bias under the selective reporting domain, there were no data left to compare. </p> </section> <section id="CD010226-sec-0178"> <h6 class="title">4.3.3 Severe adverse effects: any clinically significant severe short term adverse effects based on relevant rating scales </h6> <p>There were data reported for people leaving the study early due to severe adverse effects at short term; there was little difference in the results after removing 'high' risk studies, with placebo still favoured (non‐significantly), however heterogeneity was removed as a consequence (1 RCT, n = 24, RR 5.00, CI 0.27 to 94.34). </p> </section> <section id="CD010226-sec-0179"> <h6 class="title">4.3.4 Relapse +/‐ hospitalisation: relapse including any hospitalisation of a participant within a study </h6> <p>Again, data were reported for people leaving the study early due to relapse; after 'high' risk studies were removed from analysis, there were no data left to compare. </p> </section> </section> <section id="CD010226-sec-0180"> <h5 class="title">4.4 Imputed values</h5> <p>There were no usable continuous data and we did not impute any statistical values.</p> </section> <section id="CD010226-sec-0181"> <h5 class="title">4.5 Fixed‐effect and random‐effects</h5> <p>Random‐effects were used throughout. Within the primary outcomes, no outcomes were affected when switching to a fixed‐effect model. </p> </section> <section id="CD010226-sec-0182"> <h5 class="title">4.6 Unusual doses of trifluoperazine</h5> <p>Seven out of the 10 studies that provided data for the primary outcomes at some point, used doses of trifluoperazine above the current <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a> guidelines of 30 mg per day (<a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a>; <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>; <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>; <a href="./references#CD010226-bbs2-0004" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>; <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>; <a href="./references#CD010226-bbs2-0009" title="ReardonJD , AbramsS . Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System1966;27:265‐70. ">Reardon 1966</a>; <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a>). The range was from as low as 5 mg a day (<a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a>) to the highest dose of 80 mg a day for one of the trifluoperazine groups in <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>. Two studies used fixed doses of 15 mg a day (<a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>; <a href="./references#CD010226-bbs2-0007" title="PinardG , PrenoveauY , FliesenW , ElieR , BielmannP , LamontagneY , et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale1972;61(1):53‐66. [MEDLINE: 4561271] ">Pinard 1972</a>) and one of the trifluoperazine groups in <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> received 'low dose' of 15 mg a day. <a href="./references#CD010226-bbs2-0005" title="MarjerrisonG , IrvineD , StewartCN , WilliamsR , MatheuH , DemayM . Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal1964;60:290‐8. ">Marjerrison 1964</a> used just below 30 mg a day, with a mean of 27 mg a day. We removed the seven studies that used more than 30 mg a day from the analysis of the primary outcomes to see if this changes the estimate of the effect: </p> <p>When removing relevant studies that used more than 30 mg a day, only data for short term remained, which still demonstrated statistically significant favour for global state improvement amongst the trifluoperazine group (1 RCT, n = 40, RR 17.00 95% CI 1.05 to 276.03, <a href="./references#CD010226-fig-0005" title="">Analysis 1.1</a>). Data, after removing <a href="./references#CD010226-bbs2-0001" title="BishopMP , GallantDM , NesselhofW , SpreheDJ . A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System1964;25:674‐83. ">Bishop 1964</a> and <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a> still show favour for trifluoperazine, although this is not statistically significant (1 RCT, n = 24, RR 17.00 95% CI 1.05 to 276.03). Due to the greater power of <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>, if this study alone is removed from medium term, the data are rendered just insignificant (2 RCTs, n = 80, RR 4.90 95% CI 0.89 to 26.85, <a href="./references#CD010226-fig-0005" title="">Analysis 1.1</a>). These data do suggest that, apart from short term clinical global improvement, studies with more power and larger doses in the medium term seem to show higher levels of clinical global improvement. No other changes worthy of note occured in the other primary outcomes when looking at study doses. </p> <p>There is little difference when comparing the high dose (80 mg a day) and low dose (15 mg a day) groups with placebo in <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> when assessing levels of global improvement, with statistical significance (P = 0.04) just shown in the low‐dose group (1 RCT, n = 220, RR 4.73, CI 1.06 to 21.11, <a href="./references#CD010226-fig-0025" title="">Analysis 2.1</a>). When using higher doses of 80 mg a day, <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> records higher levels of leaving the study early due to severe adverse effects (1 RCT, n = 228, RR, 2.85, CI 0.79 to 10.24, <a href="./references#CD010226-fig-0035" title="">Analysis 3.3</a>), although not significant. <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> shows significantly more extrapyramidal adverse effects with a high dose of 80 mg a day, including akathisia (1 RCT, n = 228, RR 18.50, CI 4.58 to 74.80, <a href="./references#CD010226-fig-0037" title="">Analysis 3.5</a>) and Parkinsonism (1 RCT, n = 228, RR 3.13, CI 1.94 to 5.03, <a href="./references#CD010226-fig-0038" title="">Analysis 3.6</a>). From this relatively large study, it is shown that this higher dose seems to promote global improvement, but also cause significantly more adverse effects, especially extrapyramidal phenomenon. </p> </section> <section id="CD010226-sec-0183"> <h5 class="title">4.7 Economic outcomes</h5> <p>The effectiveness data that these values are based on, however, are based on small sample sizes and numbers of events, as well as imprecise effect estimates, as the 95% confidence interval for best estimate of effect include both no effect and appreciable benefit/harm. This calls into question the reliability of any estimated 'savings' that may be seen between groups; particularly so, as the results are merely placing a <i>value</i> on the effectiveness data, which takes into account very limited associated direct or indirect costs or resources associated with treatment. <br/> However, the same caveats remain for these assumption ‐ particularly that, even when taking into consideration the upper and lower confidence intervals of the risk ratios, one cannot ignore the unaccounted‐for costs of, for example, treatment for some of the associated adverse effects of trifluoperazine, which may‐well offset any savings. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010226-sec-0184" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010226-sec-0184"></div> <section id="CD010226-sec-0185"> <h3 class="title" id="CD010226-sec-0185">Summary of main results</h3> <section id="CD010226-sec-0186"> <h4 class="title">1. TRIFLUOPERAZINE versus PLACEBO</h4> <p>As can be seen from the <a href="./full#CD010226-tbl-0001">summary of findings Table for the main comparison</a> that, despite seven trials providing data (total n = 576), the overall quality of evidence was either low or very low, reiterating that further studies are needed. </p> <section id="CD010226-sec-0187"> <h5 class="title">1.1 Global state</h5> <p>As expected, patients with the trifluoperazine intervention showed a significant clinical improvement compared with placebo in both short and medium term, reinforcing the use of this well‐established typical antipsychotic in people with schizophrenia. </p> </section> <section id="CD010226-sec-0188"> <h5 class="title">1.2 Behaviour</h5> <p>Only one small study was usable so more studies are needed to attain a realistic view of this outcome. Nonetheless, no significant agitation was found between the two interventions. The results did demonstrate an extra patient in the trifluoperazine group classed as agitated, which could well be a reflection of the side effects of trifluoperazine, even though this drug is primarily known for its extrapyramidal side effects (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>).<br/> <br/> Even though insignificant, it is expected that adjunct sedative medication would be used more frequently in the placebo group due to the better control of symptoms and possible sedatory effects of trifluoperazine (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, <a href="./references#CD010226-bbs2-0078" title="Royal College of Psychiatrists. Antipsychotics. RCPSYCH2009. ">RCPSYCH 2009</a>). Further studies reporting this are needed.<br/> <br/> Only one small study (<a href="./references#CD010226-bbs2-0006" title="MenonMS , RamachandranV . A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research1972;14(1 January):17‐21. ">Menon 1972</a>) reported clinical improvement in behaviour as an outcome and as expected, more patients in the trifluoperazine group showed improved behaviour, again due to the antipsychotic effects of the drug and its possible sedatory effects (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, <a href="./references#CD010226-bbs2-0078" title="Royal College of Psychiatrists. Antipsychotics. RCPSYCH2009. ">RCPSYCH 2009</a>). </p> </section> <section id="CD010226-sec-0189"> <h5 class="title">1.3 Mental state</h5> <p>Even though overall no significance was shown, short‐term response in psychotic symptoms demonstrated greater intensified symptoms for people receiving placebo, favouring the trifluoperazine group; a result that is generally expected from this antipsychotic drug.<br/> <br/> In the one study that reported this outcome, trifluoperazine was found to be more effective at treating positive symptoms of delusions and hallucinations. This is again expected as typical antipsychotics, are known to have a greater effect on treating positive symptoms of schizophrenia than the negative symptoms. Newer generation atypical antipsychotics are said to be more effective than typical at treating the negative symptoms (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>; <a href="./references#CD010226-bbs2-0078" title="Royal College of Psychiatrists. Antipsychotics. RCPSYCH2009. ">RCPSYCH 2009</a>). </p> </section> <section id="CD010226-sec-0190"> <h5 class="title">1.4 Leaving the study early</h5> <p>All sub‐categories, although insignificant, did generally show more patients receiving placebo leaving the study early, with the relatively large study of <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> having significant data. <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> mentions two patients in the placebo intervention leaving the study early, one due to dysphagia and one due to a myocardial infarction; these are unlikely to be due to the placebo intervention and more likely to be due to chance and random allocation. For example, the maximum age range was up to 67 years, dysphagia and a myocardial infarction could be due to other events, even though an effort was made to exclude patients with other underlying co‐morbidities. Results were moderately heterogeneous (35%). This could well be due to the different study designs that included comparisons of other antipsychotics, as well as the setting (<a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> was the only outpatient study), patient population and demographics and the vast number of possible adverse effects that can be experienced on or off of trifluoperazine. </p> <p>For those leaving the study early due to severe adverse effects, there was no difference in the results of the meta‐analysis. To clarify, here, we defined 'severe' as any adverse effect that necessitated a patient to leave the study early. Defining a 'severe' adverse event is very subjective; any adverse effect could lead to the termination of a patient from a study if severe enough, occurring at the right time in the right individual. More severe adverse effects could potentially have been included, but due to lack of information from the trials, these data could not be determined and are represented in the outcome 'other adverse effects'. </p> </section> <section id="CD010226-sec-0191"> <h5 class="title">1.5 Extrapyramidal adverse effects</h5> <p>Our results agree with what is already well known about trifluoperazine; that it has a greater incidence of extrapyramidal effects. It was expected that more anti‐Parkinson drugs would be administered as significantly more people in the trifluoperazine group suffered general extrapyramidal adverse effects. Our results only show significance in the combined short/medium term and long term sub categories, suggesting that anti‐Parkinson drugs are not needed as often in the short term. To reliably suggest this, however, a larger study with greater power is needed. On the other hand, this result could suggest that the onset of these extrapyramidal side effects may take longer than three months. However, due to the lack of information, as the short/medium term sub category was significant, this suggests extrapyramidal results could well have occurred in the short term. The <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a> recommends that 'patients should receive an antipsychotic drug for 4–6 weeks before it is deemed ineffective', suggesting that effects could well happen in the short term.<br/> <br/> Dyskinesia occurred more frequently in the trifluoperazine group; however, between the two small studies, there is not enough power to state this as a significant result. As stated above, this may reflect dyskinesia as a later‐developing side effect of trifluoperazine use, but specific data in all three stated time frames would be needed as well as more studies to increase the power of the evidence. The larger study of <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a> was the driving‐force behind the significance of the results showing higher instances of akathisia with people receiving trifluoperazine. These results suggest that akathisia is more prevalent in those taking trifluoperazine when compared with placebo and also that akathisia is more prevalent than dyskinesia. The original review by <a href="./references#CD010226-bbs2-0092" title="MarquesLO , LimaMS , SoaresBG . Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020] ">Marques 2004</a> found that dyskinesia was more prevalent than akathisia and it is difficult to find statistical evidence elsewhere supporting this. More studies are needed. </p> </section> <section id="CD010226-sec-0192"> <h5 class="title">1.6 Other adverse effects</h5> <p>Results suggest that more patients receiving trifluoperazine experienced general adverse effects than on placebo. However, there were instances of specific adverse effects experienced with placebo, including convulsions; decreased appetite; insomnia; nausea; skin disorders and tremors. We also found that three studies each reported higher instances of seizures in the placebo group. Again, it must be noted that there was significant heterogeneity between groups for general adverse effects; more studies, with particular focus on adverse effects are needed, especially with a drug like trifluoperazine that is well known to cause them. Of note, <a href="./references#CD010226-bbs2-0010" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology1961;22(3):151‐62. [MEDLINE: 14498342] ">Schiele 1961</a> reported a highly significant prevalence of rigidity in the trifluoperazine group, which could be linked to extrapyramidal phenomenon. Hypotension and dizziness/faintness could be linked to the use of trifluoperazine and this is supported by evidence used in current guidelines (<a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>). Other adverse effects found in this review such as blurred vision, which could imply anticholinergic effects (<a href="./references#CD010226-bbs2-0092" title="MarquesLO , LimaMS , SoaresBG . Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020] ">Marques 2004</a>) and oculogyric crisis are also stated amongst the many possible adverse effects in the <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a> and the original review of <a href="./references#CD010226-bbs2-0092" title="MarquesLO , LimaMS , SoaresBG . Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020] ">Marques 2004</a>. </p> </section> <section id="CD010226-sec-0193"> <h5 class="title">1.7 Hospital and service utilisation outcomes</h5> <p>If any future studies are carried out using already hospitalised patients, this outcome could be of importance as release from hospital implies an overall clinical global improved state. Although only a small single study provided these data, results suggested release from hospital occurred more frequently in the trifluoperazine group, showing the benefit of the drug against placebo. This is an area of interest for future studies and the concept could be further transferred for potential outpatient studies under outcomes such as discharge or relief from medication. </p> </section> <section id="CD010226-sec-0194"> <h5 class="title">1.8 Economic</h5> <p>As we have stated, the current economic evidence we present uses up‐to‐date costs calculated using GBP PSSRU unit costs of health and social care; we have used BNF costs of 2013, and clinical judgement and opinions of a UK‐based mental health professional; baring this in mind, the Type C level of economic evidence used was taken from the effect of intervention data from studies that were conducted between 1961 and 1975 in the USA, Canada or India. Therefore, the international applicability of the data presented is questionable, as is the accuracy of the potential costs that may be incurred and the savings that we state have occurred due to the intervention. What the results do show us, however, is what is already known ‐ that there is a price attached to outcome measures commonly addressed in systematic reviews. This pilot economic summary is intended to highlight and promote discussion of including an economic perspective within the Cochrane Schizophrenia Group’s systematic reviews, and to encourage review authors to incorporate a user‐friendly economic analysis in reviews. It must be borne in mind that it is likely that, in clinical practice, organisation of care and treatment protocols for schizophrenia patients would all impact on care, treatment, management of side‐effects, and hospital discharge ‐ including aftercare ‐ and have very likely changed considerably since 1961‐75, which may undermine the present day applicability of the outcomes that underpin the economic analysis presented. </p> </section> </section> <section id="CD010226-sec-0195"> <h4 class="title">2. TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO</h4> <p>The only study to include specific low‐dose and high‐dose trifluoperazine was the largest study of <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>, which used a fixed dose of 15 mg a day. Even with such a large study, due to the high risk of bias associated with this study, it is difficult to have confidence in any results ‐ these should be interpreted with caution. </p> <section id="CD010226-sec-0196"> <h5 class="title">2.1 Global state; leaving the study early; adverse effects</h5> <p>Clinical improvement was significant for people receiving low‐dose trifluoperazine than for people receiving placebo. Results of the two forest plots comparing low‐dose trifluoperazine versus placebo and high‐dose trifluoperazine versus placebo also demonstrate that more people receiving a low dose improved than those receiving a high dose in the medium term. The evidence taken from this single study suggests that a lower dose leads to more effective clinical improvement than such a high dose.<br/> <br/> With a significant amount of participants leaving the study early from the placebo group, this could well be an indirect measure of acceptability of treatment, with a greater number of people receiving placebo leaving due to any reason, and due to relapse of worsening. However, results show no difference between low‐dose trifluoperazine or placebo with extrapyramidal adverse effects such as Parkinsonism and dystonia. </p> </section> </section> <section id="CD010226-sec-0197"> <h4 class="title">3. TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO</h4> <p>Again, the only study to report data for such a high dose of trifluoperazine (80 mg a day) was <a href="./references#CD010226-bbs2-0008" title="PrienRF , LevineJ , ColeJO . High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry1969;126(3):305‐13. [MEDLINE: 4895559] ">Prien 1969*</a>. </p> <section id="CD010226-sec-0198"> <h5 class="title">3.1 Global state; leaving the study early; adverse effects</h5> <p>It would be considered unethical nowadays to undertake a study that directly compares such high doses of trifluoperazine to either placebo or a low dose. The results for clinical improvement from all pooled trifluoperazine versus placebo studies (with a total n = 513) employ a mean of 33 mg/day ‐ a dose that we now consider high based on the <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a> recommendations, but which at the time of the studies (between 37 to 52 years ago) showed clinical improvement. This single study, with a high dose of 80 mg/day, did not yield significant results as regards clinical improvement and showed that a significantly greater amount of extrapyramidal symptoms (akathisia; Parkinsonism; dystonia) were experienced by people in the high‐dose group compared to placebo. These results indicate that exceptionally high doses will not serve to improve global state, nor limit risk of extrapyramidal side effects (EPS). However, greater numbers of people taking placebo left the study early due to any reason, including relapse or worsening. This indirect measure of acceptability of treatment is more in favour of high‐dose trifluoperazine, but at the cost of greater losses of trifluoperazine participants due to severe adverse effects. </p> <p>Again, due to the high risk of bias associated with this study, results need interpreting with caution. </p> </section> </section> </section> <section id="CD010226-sec-0199"> <h3 class="title" id="CD010226-sec-0199">Overall completeness and applicability of evidence</h3> <section id="CD010226-sec-0200"> <h4 class="title">1. Completeness</h4> <p>Apart from <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a>, which mentioned obtaining consent from patients' families, no other study gave any insight into how and even if consent was obtained from the patients or their relatives/next of kin to take part in the trial, which leaves a question mark over the ethics of these trials. Futhermore, <a href="./references#CD010226-bbs2-0002" title="ClarkML , ParedesA , CostiloeJP , WoodF , BarrettA . Loxapine in newly admitted chronic schizophrenic patients. Journal of Clinical Pharmacology1975;15(4 Pt 1):286‐94. [MEDLINE: 1092725] ">Clark 1975</a> was the only study to mention how they randomly allocated the patients in the trial (block randomisation). This leaves an unclear risk of allocation bias for all of the remaining studies.<br/> There were a large number of small studies included from many years ago (<a href="./references#CD010226-bbs2-0092" title="MarquesLO , LimaMS , SoaresBG . Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020] ">Marques 2004</a>). So not only were all the trials pre‐CONSORT (<a href="./references#CD010226-bbs2-0072" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285(12):1987‐91. ">Moher 2001</a>), but the data provided were very limited and, of the data that were provided, only a portion could be used due to incompleteness. No contact with the original authors was possible due to the length of time that has lapsed, therefore further data could not be obtained for use in the review.<br/> <br/> Future studies, if any, must follow CONSORT (<a href="./references#CD010226-bbs2-0072" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285(12):1987‐91. ">Moher 2001</a>) and include or make all data freely accessible whether used or not. Data must be clearly presented in visual tables and written format and state exactly what is being measured as well as how and when it is being measured. For example, number of adverse effects experienced by a patient; time frame; what they experienced and how often. Other outcomes such as patient satisfaction; quality of life and economic outcomes were not assessed. </p> </section> <section id="CD010226-sec-0201"> <h4 class="title">1. Applicability</h4> <p>All studies apart from <a href="./references#CD010226-bbs2-0003" title="GrossHS . A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental1974;16(7):696‐705. ">Gross 1974</a> were conducted in a hospital setting. Nowadays, with schizophrenia being diagnosed earlier and treatment provided earlier (<a href="./references#CD010226-bbs2-0080" title="Royal College of Psychiatrists. Schizophrenia. RCPSYCH2011. ">RCPSYCH 2011</a>), prognosis is better, with more care provided in the community, so these older studies do not reflect this transition.<br/> <br/> Many studies excluded participants with co‐morbidities to reduce the risk of bias of the results and outcomes. Many studies also used higher than <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a> recommended daily doses of trifluoperazine. This does occur in practice; if higher doses are needed to control symptoms then anti‐Parkinson drugs are often administered to try and limit, in particular, extrapyramidal effects (<a href="./references#CD010226-bbs2-0078" title="Royal College of Psychiatrists. Antipsychotics. RCPSYCH2009. ">RCPSYCH 2009</a>). </p> <p>There are no Type A or B economic evaluations conducted on trifluoperazine. With Type C data, which report outcome measures, we have attempted to value the outcomes in GBP terms. This may not be an accurate measure of costs incurred or saved and as such we would not recommend that these results be used. This is a pilot study and we intended to encourage debate on how best to use such reported data. </p> </section> </section> <section id="CD010226-sec-0202"> <h3 class="title" id="CD010226-sec-0202">Quality of the evidence</h3> <section id="CD010226-sec-0203"> <h4 class="title">1. General</h4> <p>Of the 10 included studies, all are pre‐CONSORT (<a href="./references#CD010226-bbs2-0072" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285(12):1987‐91. ">Moher 2001</a>) and are graded either low or very low quality.To a large extent, these studies have not mentioned that they followed a specific method of randomisation and much of the data was unusable. </p> </section> <section id="CD010226-sec-0204"> <h4 class="title">2. Specific</h4> <p>Ten studies with a total number 686 relevant participants featured in 20 outcomes in this review. The results showed that there was a global improvement in patients’ mental health status. Although these studies have shown improvement in patients’ mental health status, they have not methodologically followed randomised clinical trials designs.  </p> <section id="CD010226-sec-0205"> <h5 class="title">2.1 Economic evaluation</h5> <p>We did not come across any studies that were of Type A or B economic evaluation (which includes but not limited to cost‐effectiveness analysis, cost‐utility analysis and cost‐benefit analysis). </p> </section> </section> </section> <section id="CD010226-sec-0206"> <h3 class="title" id="CD010226-sec-0206">Potential biases in the review process</h3> <p>The data extraction was conducted by researchers KM and EH, with review author KK independently extracting data for a second time from all included 10 studies. The reviews were cross‐checked by a fourth independent review author. Bias may be introduced through the extraction process but efforts beyond stated in the protocol have been employed to try reduce this. </p> </section> <section id="CD010226-sec-0207"> <h3 class="title" id="CD010226-sec-0207">Agreements and disagreements with other studies or reviews</h3> <p>This review focused on trifluoperazine versus placebo. In general, the results of this review come in line with the review conducted by <a href="./references#CD010226-bbs2-0092" title="MarquesLO , LimaMS , SoaresBG . Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020] ">Marques 2004</a> who indicate that  trifluoperazine is more effective in comparison to placebo (as well as other treatments). </p> <section id="CD010226-sec-0208"> <h4 class="title">Limitations of the review</h4> <p>The study authors appreciate the limitations of the methods used in the economic summary. It is fair to say that the data provided display a rudimentary estimate of the value in GBP terms associated with the outcomes of relapse and hospital discharge. As proxy measures are used for total costs, it is acknowledged that the cost of treatment may well change the direction of the estimated result. The aim of piloting this economic summary is to generate debate and discussion; to not take effectiveness data at face value without considering potential economic consequences; and to utilise the data in a way that will be of greater use to decision/policy‐makers. We will welcome discussion on the methods used for Type C level economic evidence and the planned methods described for Type A and B level evidence should future reviews find those studies. We are aware that policy‐makers and commissioners often consider these reviews while deciding on service provision and valuing outcomes in GBP terms may make it easier to review evidence such as relapse. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010226-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010226-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: economic summary (2013)" data-id="CD010226-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram: economic summary (2013)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010226-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010226-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 1 Global state: 1. clinical improvement (as defined by each study)." data-id="CD010226-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 1 Global state: 1. clinical improvement (as defined by each study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 2 Behaviour: 1. any clinically significant agitation or distress (as defined by each study)." data-id="CD010226-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 2 Behaviour: 1. any clinically significant agitation or distress (as defined by each study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 3 Behaviour: 2. use of adjunctive medication for sedation." data-id="CD010226-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 3 Behaviour: 2. use of adjunctive medication for sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 4 Behaviour: 3. clinical improvement (as defined by each study)." data-id="CD010226-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 4 Behaviour: 3. clinical improvement (as defined by each study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 5 Mental state: 1. any clinically significant response in psychotic symptoms (as defined by each study)." data-id="CD010226-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 5 Mental state: 1. any clinically significant response in psychotic symptoms (as defined by each study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 6 Mental state: 2. any clinically significant response in positive symptoms." data-id="CD010226-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 6 Mental state: 2. any clinically significant response in positive symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 7 Leaving the study early: 1. any reason." data-id="CD010226-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 7 Leaving the study early: 1. any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 8 Leaving the study early: 2. severe adverse effects." data-id="CD010226-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 8 Leaving the study early: 2. severe adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 9 Leaving the study early: 3. due to relapse or worsening." data-id="CD010226-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 9 Leaving the study early: 3. due to relapse or worsening. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 10 Extrapyramidal adverse effects: 1. general." data-id="CD010226-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 10 Extrapyramidal adverse effects: 1. general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 11 Extrapyramidal adverse effects: 2. use of anti‐Parkinson drugs." data-id="CD010226-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 11 Extrapyramidal adverse effects: 2. use of anti‐Parkinson drugs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 12 Extrapyramidal adverse effects: 3. dyskinesia." data-id="CD010226-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 12 Extrapyramidal adverse effects: 3. dyskinesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 13 Extrapyramidal adverse effects: 4. akathisia." data-id="CD010226-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 13 Extrapyramidal adverse effects: 4. akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 14 Extrapyramidal adverse effects: 5. Parkinsonism." data-id="CD010226-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 14 Extrapyramidal adverse effects: 5. Parkinsonism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 15 Extrapyramidal adverse effects: 6. dystonia." data-id="CD010226-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 15 Extrapyramidal adverse effects: 6. dystonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 16 Other adverse effects: 1. general." data-id="CD010226-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 16 Other adverse effects: 1. general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 17 Other adverse effects: 2. specific." data-id="CD010226-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 17 Other adverse effects: 2. specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 18 Other adverse effects: 3. laboratory data." data-id="CD010226-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 18 Other adverse effects: 3. laboratory data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 19 Hospital and service utilisation outcomes: 1. hospital transfer/ home leave." data-id="CD010226-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 19 Hospital and service utilisation outcomes: 1. hospital transfer/ home leave. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 20 Hospital and service utilisation outcomes: 2. hospital discharge." data-id="CD010226-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 TRIFLUOPERAZINE versus PLACEBO, Outcome 20 Hospital and service utilisation outcomes: 2. hospital discharge. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 1 Global state: 1. clinical improvement (as defined by each study)." data-id="CD010226-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 1 Global state: 1. clinical improvement (as defined by each study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 2 Leaving the study early: 1. any reason." data-id="CD010226-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 2 Leaving the study early: 1. any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 3 Leaving the study early: 2. severe adverse effects." data-id="CD010226-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 3 Leaving the study early: 2. severe adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 4 Leaving the study early: 3. due to relapse or worsening." data-id="CD010226-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 4 Leaving the study early: 3. due to relapse or worsening. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 5 Extrapyramidal adverse effects: 2. akathisia." data-id="CD010226-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 5 Extrapyramidal adverse effects: 2. akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 6 Extrapyramidal adverse effects: 3. Parkinsonism." data-id="CD010226-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 6 Extrapyramidal adverse effects: 3. Parkinsonism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 7 Extrapyramidal adverse effects: 4. dystonia." data-id="CD010226-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 7 Extrapyramidal adverse effects: 4. dystonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 8 Other adverse effects: 2. specific." data-id="CD010226-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO, Outcome 8 Other adverse effects: 2. specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 1 Global state: 1. clinical improvement (as defined by each study)." data-id="CD010226-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 1 Global state: 1. clinical improvement (as defined by each study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 2 Leaving the study early: 1. any reason." data-id="CD010226-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 2 Leaving the study early: 1. any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 3 Leaving the study early: 2. severe adverse effects." data-id="CD010226-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 3 Leaving the study early: 2. severe adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 4 Leaving the study early: 3. due to relapse or worsening." data-id="CD010226-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 4 Leaving the study early: 3. due to relapse or worsening. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 5 Extrapyramidal adverse effects: 1. akathisia." data-id="CD010226-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 5 Extrapyramidal adverse effects: 1. akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 6 Extrapyramidal adverse effects: 2. Parkinsonism." data-id="CD010226-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 6 Extrapyramidal adverse effects: 2. Parkinsonism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 7 Extrapyramidal adverse effects: 3. dystonia." data-id="CD010226-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 7 Extrapyramidal adverse effects: 3. dystonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010226-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/urn:x-wiley:14651858:media:CD010226:CD010226-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_t/tCD010226-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 8 Other adverse effects: 1. specific." data-id="CD010226-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO, Outcome 8 Other adverse effects: 1. specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/media/CDSR/CD010226/image_n/nCD010226-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010226-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Suggested design for future research</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, clearly described, concealed.<br/> Blindness: double, described and tested.<br/> Duration: 12 months. </p> <p>Setting: community.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia or schizophrenia‐like illness, clearly described and documented.<br/> N = 600.*<br/> Age: any.<br/> Sex: both.<br/> Exclusion: none but full medical history must be taken into account as well as thorough health state evaluation to reduce potential confounders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Oral trifluoperazine: dose flexible within current guideline recommended limits <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, N = 150.<br/> 2. Oral clozapine: dose flexible within current guideline recommended limits <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, N = 150. </p> <p>3. Oral atypical antipsychotic: dose flexible current guideline within recommended limits <a href="./references#CD010226-bbs2-0031" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>, N = 150. </p> <p>**4. Oral placebo: N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All outcomes are grouped by time measured at: one month, three months, six months, nine months and 12 months.<br/> Mortality.<br/> Specific behaviours ‐ self‐harm, including suicide, injury to others, aggression.<br/> Global outcomes ‐ overall improvement, use of any relevant additional medication, relapse.<br/> Service outcomes ‐ hospital admission and duration of stay, for any reason.<br/> Mental state ‐ no clinically important change in general mental state, no clinically important change in psychotic symptoms, broken down into positive and negative symptoms.<br/> Adverse effects ‐ clinically important adverse effects, defining severe adverse effects and including all extrapyramidal phenomena.<br/> Leaving the study early ‐ any reason; severe adverse effects.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜20% between groups for primary outcome with adequate degree of certainty. </p> <p>** Issues about how ethical it is to give placebo to patients suffering with schizophrenia may arise, especially when all these drugs have been shown to be more beneficial than placebo in past RCTs. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p>RCT ‐ randomised controlled trial</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Suggested design for future research</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010226-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TRIFLUOPERAZINE versus PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TRIFLUOPERAZINE versus PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> TRIFLUOPERAZINE versus PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TRIFLUOPERAZINE versus PLACEBO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state ‐ clinical improvement ‐ medium term</b> <br/> As defined by each study<br/> Follow‐up: mean 19 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.61</b> <br/> (1.54 to 13.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>417<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> <br/> (31 to 282)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> <br/> (29 to 263)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state ‐ relapse or worsening ‐ medium term</b> <br/> Numbers of participants experiencing relapse/worsening<br/> Follow‐up: mean 5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.34</b> <br/> (0.23 to 0.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>381<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (90 to 191) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b> <br/> (58 to 123) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state ‐ any clinically significant response in psychotic symptoms (as defined by each study) ‐ medium term</b> <br/> Numbers of participants experiencing 'intensified symptoms'<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.54 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>80<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b> <br/> (122 to 461) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b> <br/> (122 to 461) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early ‐ any reason ‐ medium term</b> <br/> Number of participants leaving the studies early<br/> Follow‐up: mean 5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.38 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>523<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,8,11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>336 per 1000</b><sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> <br/> (128 to 400) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b><sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (44 to 137) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Severe adverse effects ‐ short term</b> <br/> Numbers of participants leaving the studies due to severe adverse effects<br/> Follow‐up: mean 2 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.31</b> <br/> (0.22 to 7.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>67<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>8,9,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b> <br/> (17 to 600) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b><sup>1,2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> <br/> (16 to 554) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Behaviour ‐ any clinically significant agitation or distress ‐ medium term</b> <br/> As defined by each study<br/> Follow‐up: 4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (7 to 797) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2</b> <br/> (0.19 to 20.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Moderate risk relates to the population percentage in the control group.<br/> <sup>2</sup> Median control group risk presented.<br/> <sup>3</sup> Data were presented as the positive outcome of 'clinical improvement' so the higher value indicates a favourable outcome.<br/> <sup>4</sup> Risk of bias: 'serious' ‐ 33% of the studies rated as a 'high' risk or bias over one or more of the domains; 100% of the included studies did not adequately describe randomisation methods.<br/> <sup>5</sup> Indirectness: 'serious' ‐ only 33% of the studies directly compared trifluoperazine to a placebo whereas 67% had other drug interventions in their respective trials.<br/> <sup>6</sup> Risk of bias: 'serious' ‐ 100% of the studies rated as a 'high' risk or bias over one or more of the domains; 100% of the included studies did not adequately describe randomisation methods.<br/> <sup>7</sup> Indirectness: 'serious' ‐ 50% of the studies directly compared trifluoperazine to a placebo whereas the remaining 50% had other drug interventions in their respective trials.<br/> <sup>8</sup> Imprecision: 'serious' ‐ 95% confidence intervals for best estimate of effect include both 'no effect' and appreciable benefit/harm.<br/> <sup>9</sup> Indirectness: 'serious' ‐ 100% had other drug interventions in their respective trials.<br/> <sup>10</sup> Note: moderate heterogeneity between studies.<br/> <sup>11</sup> Inconsistency: 'serious' ‐ moderate heterogeneity evident (I<sup>2</sup> = 47%).<br/> <sup>12</sup> Indirectness: 'serious' ‐ 20% of the studies directly compared trifluoperazine to a placebo whereas the remaining 80% had other drug interventions in their respective trials.<br/> <sup>13</sup> Risk of bias: 'serious' ‐ 50% of the studies rated as a 'high' risk or bias over one or more of the domains; 50% of the included studies did not adequately describe randomisation methods. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TRIFLUOPERAZINE versus PLACEBO for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010226-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Economic summary</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Perspective</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of Economic Evaluation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Resource Use provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Unit Costs Provided</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICER</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QALY/DALY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Net Benefit Ratio</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grading</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Economic summary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010226-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Economic studies: excluded</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for exclusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study type</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0034" title="DaviesLM , LewisS , JonesPB , BarnesTR , GaughranF , HayhurstK , et al. Cost‐effectiveness of first‐ v. second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry2007;191:14‐22. ">Davies 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: first vs second generation antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0043" title="FilippelliE , BiricoltiG , ScaranoC , RussoF , LucianoL . Treatment of psychotic disorders with olanzapine, risperidone and typical neuroleptics: a comparative cost‐effectiveness evaluation in a local psychiatric setting. Farmeconomia e Percorsi Terapeutici2005;6(3):161‐8. ">Filippelli 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: atypical vs typical antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0045" title="GalvinPM , KnezekLD , RushAJ , TopracMG , JohnsonB . Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clinical Therapeutics1999;21(6):1105‐16. ">Galvin 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: not randomised.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0046" title="GhaemiSN , KirkwoodCK , SamburMR , KoJY , HowdenKL , DuongQ , et al. Economic outcomes of risperidone in comparison to typical neuroleptic agents for treatment‐resistant psychosis: a community‐based study. Journal of Pharmacy Technology2001;17:273‐8. ">Ghaemi 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: not randomised.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0050" title="HanrahanP , LuchinsDJ , FabianR , TolleyG . Cost‐effectiveness of atypical antipsychotic medications versus conventional medication. Expert Opinion in Pharmacotherapy2006;7(13):1749‐58. ">Hanrahan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: atypical vs conventional antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0058" title="KnappM , WindmeijerF , BrownJ , KontodimasS , TzivelekisS , HaroJM , et al. Cost‐utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan‐European SOHO study. PharmacoEconomics2008;26(4):341‐58. ">Knapp 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: olanzapine vs other antipsychotics.</p> <p>Outcomes: no specific outcome measures for trifluoperazine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0064" title="LewisR . Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian Journal of Psychiatry1998;43(6):596‐604. ">Lewis 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0065" title="LewisSW , DaviesL , JonesPB , BarnesTRE , MurrayRM , KerwinR , et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment2006;10(17):1‐182. ">Lewis 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0069" title="MartinJL , PerezV , SacristanM , Rodriguez‐ArtalejoF , MartinezC , AlvarezE . Meta‐analysis of drop‐out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry2006;21(1):11‐20. ">Martin 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0073" title="MouldQJ , ContrerasHI , VerduzcoW , MejiaAJM , GardunoEJ . Cost‐effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics. Revista de Psiquiatrí́a y Salud Mental2009;2(3):108‐18. ">Mould 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised.</p> <p>Particiapants: schizophrenia.</p> <p>Interventions: cost and effectiveness of ziprasidone, olanzapine, risperidone, haloperidol and clozapine (not trifluoperazine). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0084" title="StargardtT , WeinbrennerS , BusseR , JuckelG , GerickeCA . Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Journal of Mental Health Policy and Economics2008;11(2):89‐97. ">Stargardt 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: not randomised.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010226-bbs2-0085" title="SuttajitS , SrisurapanontM , ManeetonB , ManeetonN , SuttajitS . Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007815] ">Suttajit 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (systematic review).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Economic studies: excluded</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010226-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Economic studies: awaiting classification</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mapelli 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Awaiting classification.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full article not obtained.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mauskopf 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Awaiting classification.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full article not obtained.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percudani 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Awaiting classification.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full article not obtained.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Economic studies: awaiting classification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010226-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Economic: Differences in resource use using Relative Risk (RR)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Resource</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Base case</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Favouring trifluoperazine (CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Favouring placebo (CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>RR</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Trifluoperazine</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Placebo</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>RR</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Trifluoperazine</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Placebo</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>RR</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Trifluoperazine</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Placebo</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjunctive medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Use of anti‐parkinson drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£25.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£11.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£57.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£4.32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment for akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£8.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£2.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£30.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£2704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5408</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1930.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5418.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£1367.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5418.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£2806.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>£5418.86</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Economic: Differences in resource use using Relative Risk (RR)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/full#CD010226-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010226-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TRIFLUOPERAZINE versus PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. clinical improvement (as defined by each study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.44 [2.72, 15.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.93 [2.74, 43.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.61 [1.54, 13.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Behaviour: 1. any clinically significant agitation or distress (as defined by each study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 20.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Behaviour: 2. use of adjunctive medication for sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.34, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.24, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behaviour: 3. clinical improvement (as defined by each study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.0 [1.71, 425.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1. any clinically significant response in psychotic symptoms (as defined by each study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.32, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 intensified symptoms ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.09, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 intensified symptoms ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.54, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2. any clinically significant response in positive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 delusions or hallucinations ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.03, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.45, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.40, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.45, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.17, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Leaving the study early: 2. severe adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.62, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.22, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.46, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.56, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Leaving the study early: 3. due to relapse or worsening <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.25, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.15, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.23, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Extrapyramidal adverse effects: 1. general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [1.28, 6.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [1.36, 17.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.86, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Extrapyramidal adverse effects: 2. use of anti‐Parkinson drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.91 [2.64, 13.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.36, 24.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [1.11, 18.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.5 [2.78, 25.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Extrapyramidal adverse effects: 3. dyskinesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.33, 27.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.33, 27.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Extrapyramidal adverse effects: 4. akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.78 [3.06, 37.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.26, 95.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.79 [3.17, 51.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Extrapyramidal adverse effects: 5. Parkinsonism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [0.54, 21.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.0 [0.94, 239.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.19, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Extrapyramidal adverse effects: 6. dystonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.94, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Other adverse effects: 1. general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.77, 4.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.98 [1.94, 100.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.61, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.37, 15.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Other adverse effects: 2. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 anorexia ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 blurred vision ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 blurred vision ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.26, 98.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 convulsions ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 decreased appetite ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 dermatitis ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7 dermatosis ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.08, 29.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8 difficulty swallowing ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.11, 9.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.9 dizziness/faintness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.21 [0.54, 156.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.10 drowsiness ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.40, 122.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.11 drowsiness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [0.76, 7.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.12 edema of face ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.13 fainting ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.38 [0.42, 27.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.14 fever ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.15 hypersalivation ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.20, 20.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.16 hypotension ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.70, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.17 incontinence of urine ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.18 incoordination ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.5 [0.83, 14.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.19 insomnia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.20 insomnia ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.39, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.21 lethargy ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.53, 152.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.22 lethargy ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.23 motor restlessness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.24 muscular weakness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.26, 98.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.25 myocardial infarction ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.26 nausea ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.27 nausea/ vomiting ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.21, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.28 need for sedatives ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.65, 6.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.29 oculogyric crisis ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.30 photosensitivity ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.25, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.31 polydipsia and polyuria ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.32 rigidity ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [1.25, 64.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.33 seizures ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.09, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.34 skin disorder ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.35 skin rashes ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.20, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.36 slurred speech ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.37 spasm muscles of mastication ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.38 tenseness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.39 tremor ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.40 tremor ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Other adverse effects: 3. laboratory data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 elevated blood urea nitrogen ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 eosinophilia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 leucocytosis ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.21, 19.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 mild elevation in blood pressure ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.20, 20.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 mild elevation of alkaline phosphate ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.6 minor primary T‐wave changes ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7 sinus bradycardia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8 sinus tachycardia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.9 weight loss (&gt;10 lb) ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.45, 8.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.10 weight gain (&gt;10 lb) ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.21, 19.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Hospital and service utilisation outcomes: 1. hospital transfer/ home leave <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.08, 15.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Hospital and service utilisation outcomes: 2. hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.58 [0.44, 132.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TRIFLUOPERAZINE versus PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010226-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. clinical improvement (as defined by each study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.73 [1.06, 21.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.25, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 2. severe adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early: 3. due to relapse or worsening <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.25, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Extrapyramidal adverse effects: 2. akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.88 [1.60, 29.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Extrapyramidal adverse effects: 3. Parkinsonism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Extrapyramidal adverse effects: 4. dystonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.44, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Other adverse effects: 2. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 decreased appetite ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 dizziness/faintness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.88 [0.36, 131.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 drowsiness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.33, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 fainting ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [0.58, 41.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 hypotension ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.79, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 insomnia ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.24, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 nausea/ vomiting ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.11, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 photosensitivity ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.11, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 seizures ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 skin rashes ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.20, 4.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TRIFLUOPERAZINE (LOW DOSE) versus PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010226-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. clinical improvement (as defined by each study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.52, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 1. any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.30, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 2. severe adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.79, 10.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early: 3. due to relapse or worsening <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.17, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Extrapyramidal adverse effects: 1. akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.50 [4.58, 74.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Extrapyramidal adverse effects: 2. Parkinsonism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [1.94, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Extrapyramidal adverse effects: 3. dystonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.31, 4.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Other adverse effects: 1. specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 decreased appetite ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.35, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 dizziness/faintness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.34 [0.70, 216.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 drowsiness ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.88, 5.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 fainting ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.17, 20.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 hypotension ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.51, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 insomnia ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.50, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 nausea/ vomiting ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.22, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 photosensitivity ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.29, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 seizures ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.06, 14.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 skin rashes ‐ short/medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.11, 3.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">TRIFLUOPERAZINE (HIGH DOSE) versus PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010226.pub2/references#CD010226-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010226.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010226-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010226-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010226-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010226-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010226\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010226\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010226\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010226\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010226\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010226.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010226.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010226.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010226.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010226.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717536516"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010226.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717536520"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010226.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dba509d629371',t:'MTc0MDcxNzUzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 